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SUMMARY 
Heparan sulphates (HS) are highly sulphated, linear polysaccharides that are a major 
component of the extracellular matrix. Their innate ability to bind, stabilise and 
potentiate a range of biologically relevant proteins, while remaining stable themselves 
over prolonged periods, makes them ideally suited for the development of off-the-
shelf therapies. 
Transforming growth factor-β1 (TGF-β1), a potent heparin-binding growth 
factor, is known to initiate many of the key signalling events driving connective tissue 
repair. The clinical utility of exogenous TGF-β1 has been limited by the 
supraphysiological doses needed to overcome its rapid clearance, doses which have 
been associated with adverse events such as synovial inflammation, fibrosis and in 
extreme cases, cancer. Additionally, age-related decreases in TGF-β1 efficacy have 
been reported in both small and large animal models, which further limits its potential 
use in patients of advanced years.  
In response to these challenges, new strategies are being developed that reduce 
or completely remove the need for exogenous use of TGF-β1. Such strategies aim to 
better control the biodistribution and release kinetics of TGF-β1 in an attempt to 
sustain its bioactivity once administered. Most recently, our lab has pioneered efforts 
to develop HS-based glycotherapeutic agents which both enhance the bioactivity of, 
and remove the need for any exogenous application of growth factors. 
 Here we report the identification of the structural determinants of the heparin-
TGF-β1 interaction, and the subsequent development of an HS variant with targeted 
affinity for TGF-β1, subsequently termed HS16+ve. Application of this HS was posited 
to bind and potentiate the activity of endogenous TGF-β1 present at the site of 
cartilage injury, so removing the need for its exogenous application.  
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I first examined the structural determinants of the interaction between TGF-β1 
and heparin, a highly sulphated form of HS that is often used as an analogue to study 
protein-HS interactions, and investigated how these determinants affect the ability of 
heparan sugars to modulate the bioactivity of TGF-β1. Next, using a peptide-based 
affinity chromatography platform, I isolated HS16
+ve
 and demonstrated that it is 
compositionally distinct from the non-TGF-β1-binding HS, HS16-ve, and the original 
porcine mucosal HS preparation used for HS16
+ve
 production. This difference in 
composition was shown to have functional consequences for the modulation of the 
bioactivity of both TGF-β1, and the structurally related bone morphogenetic protein-2 
(BMP-2). I also examined the effects of HS16
+ve
 on TGF-β1 driven chondrogenic 
differentiation of MSCs in vitro. Finally, using a rabbit model for cartilage injury, I 
investigated the ability of HS16
+ve
 to augment the cartilage healing response relative 
to the current standard of care.  
The work presented here allows one to assert that such heparin:HS 
comparisons can serve as efficient templates for the development of HS variants for 
other clinically relevant growth factors. It also paves the way for further studies of 
TGF-β1-HS interaction, and will serve to aid the development of HS-based strategies 
to regulate MSC behaviour for tissue repair.  
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CHAPTER 1. LITERATURE REVIEW 
1.1. Introduction 
Protein growth factors are a structurally diverse class of proteins that potently 
drive the growth, proliferation and differentiation of cells. The strong influence they 
wield over cell behaviour has led to their emergence as leading candidates in the 
development of tissue repair strategies. This has made them the epicentre of research 
into therapeutic strategies that include stem cell expansion [1, 2], skin healing [3, 4], 
angiogenesis [5, 6], bone healing [7-10] and cartilage repair [11-16]. Unfortunately, 
their potency is as much bane as it is boon as the same mechanisms that drive cell 
growth and proliferation can also drive cancer development [17]. Research is 
therefore shifting to focus on the development of tissue repair strategies that reduce or 
remove the need for exogenous growth factor administration. Such methods may rely 
on the sequestration of endogenous growth factors with self-assembling peptides [18, 
19], the use of scaffold or carriers to modulate growth factor release [8, 20] or the 
induction of more appropriate, endogenous growth factor production [21].  
Heparan sulphates have emerged as candidates for the sequestration and 
potentiation of growth factor activity [22-24]. Their innate ability to bind and 
potentiate a range of biologically relevant proteins [25], while remaining stable over 
prolonged periods [26], makes them ideally suited for the development of off-the-
shelf therapies. This collection of studies thus aims to examine the interaction 
between HS and TGF-β1, with an eye towards the development of a therapeutically 
relevant TGF-β1-binding HS variant. 
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1.2. Growth factors in tissue regeneration 
Growth factors are potent protein molecules that direct or strongly influence 
cell fate and behaviour. They serve as messengers between cells and normally relay 
their messages by binding to cognate cell surface receptors. The precise effect of a 
given growth factor is determined by a number of factors that include the responding 
cell type, the concentration of the factor, and the presence of other stimuli [27]. 
During development, growth factor gradients establish embryonic patterning and 
selectively promote cell proliferation or differentiation and maturation. Such gradients 
need to be very finely tuned as dysregulation often results in developmental 
abnormalities [28, 29]. It has been well established in Drosophila that the 
establishment and maintenance of such gradients, particularly the Wnts and 
Hedgehogs, depends on the appropriate expression of heparan sulphates [30]. It is also 
exemplified by the ability of ectopically applied fibroblast growth factors (FGFs) to 
induce the formation of additional limbs in developing chick embryos [31].   
When a wound is sustained, the body attempts to heal itself by recapitulating 
these early developmental processes. The wound-healing process begins with the 
initiation of haemostasis, which involves vascular constriction and platelet 
aggregation, degranulation and fibrin formation. Inflammatory processes such as 
neutrophil, lymphocyte and monocyte infiltration and differentiation to macrophages 
mark the start of the inflammation phase, which is then followed by the proliferation 
phase, where re-epithelialisation, angiogenesis, collagen synthesis and ECM 
formation occur. Finally, the initiation of tissue remodelling marks the final phase in 
the wound-healing process and involves collagen remodelling and vascular 
maturation and regression [32, 33]. 
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During each of these phases, cascades of growth factors are released in an 
attempt to recruit and stimulate the proliferation and differentiation of cells to replace 
the damaged tissue. However, the environment seen by cells during wound healing is 
vastly different from that experienced during embryonic development. Aside from the 
proliferation and differentiation cues being received, cells in a wound site are also 
bombarded with a barrage of inflammatory signals, and intrinsic tissue signals that 
attempt to maintain the local tissue phenotype [32]. A good healing outcome would 
therefore require that the growth factor signal be strong enough to overcome these 
competing signals. The use of exogenous growth factors presents a simple, 
straightforward method for achieving this. 
1.2.1. Current practice 
 The sheer simplicity of exogenous growth factor application to promote tissue 
repair has seen the development of several recombinant growth factor-based products 
for clinical use - Regranex
®
, an FDA-approved recombinant platelet-derived growth 
factor therapy for the treatment of diabetic foot ulcers [34]; Infuse
®
, a recombinant 
bone morphogenetic protein-2 (BMP-2) therapy for spinal fusion [35]; and 
Palifermin, a recombinant keratinocyte growth factor (FGF-7) drug used 
prophylactically to reduce the chances of mucositis developing in cancer patients 
during chemo- or radiation therapy [36]. Most recently, the FDA has also approved 
Augment
TM
 Bone Graft, a platelet-derived growth factor-BB (PDGF-BB)-based bone 
graft substitute, for use during ankle and hindfoot fusion [37]. 
Tissue engineering research has also focused on the use of growth factors to 
drive production of the desired tissue/cells. Many groups often incorporate exogenous 
recombinant growth factor into their tissue constructs to help direct cell behaviour 
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towards the desired outcome [38, 39]. However, this direct, even simplistic, approach 
to tissue repair and engineering is not without its drawbacks. 
1.2.2. Challenges in the use of GFs for tissue regeneration 
 As alluded to earlier, the natural potency of growth factors is a double-edged 
sword. Their mitogenic abilities can easily make them carcinogenic if regulatory 
controls are lost, which explains their normally low concentrations and tight 
regulation in vivo. Binding of growth factors to their cognate receptors is often 
accompanied by the rapid internalisation and degradation of the receptor-ligand 
complex [27], while unbound growth factors are rapidly cleared by serum albumin, 
enzymatic degradation or deactivation [40-42]. The challenge therein lies in 
maintaining efficacious concentrations of growth factor within the intended treatment 
site, as endogenous levels are often drowned out by the “relative bombardment” cells 
experience in a wound site, and growth factors will have varying half-lives. 
 A common approach adopted to overcome this challenge is the use of high, 
often supraphysiological, doses of the growth factor [34, 35]. Such a strategy ensures 
the maintenance of effective doses of growth factor within the treatment site, by 
counteracting the effects of the growth factor’s half-life. This extended persistence 
also compensates for growth factor loss from diffusion out of the treatment site. 
Unfortunately, the use of recombinant growth factors is particularly costly, due to 
challenges associated with large scale production, storage, transport and the long-term 
stability of proteins. Additionally, the use of growth factors always poses the risk of 
eliciting an immune reaction, given the inherent immunogenicity of proteins and 
peptides [43]. The recent report on complications, which include tissue swelling, 
arising from the off-label use of Medtronic’s Infuse BMP-2 therapy stands as a 
testament to these risks [10]. 
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Efforts to overcome these challenges have often involved the design and use 
of better carriers to store and regulate the release of the growth factor(s) [44]. 
Significant advances have been made in the push to improve the delivery of growth 
factors for tissue engineering through the development of more chemically versatile 
scaffolds, and improved techniques for growth factor incorporation. Such techniques 
are now providing unprecedented levels of spatio-temporal control over the location 
and bioactivity of delivered growth factors in the body [45]. However, while 
appearing promising, such approaches are not quite able to address the issue of the 
supraphysiological dosing of growth factors. These approaches are akin to building a 
dam across a swelling river to control its flow - everything works fine as long as the 
dam remains intact. Some groups have attempted to circumvent this with the use of 
mRNA or DNA constructs instead of proteins [21, 46], but these approaches border 
on becoming gene therapy, which faces a plethora of its own regulatory hurdles. 
An interesting alternative to this approach would be the enhancement of native 
growth factor potency in situ. This approach would rely heavily on an understanding 
of the signalling mechanism of the targeted growth factor, and an understanding of its 
natural enhancers and inhibitors. HS has been shown to be heavily involved in the 
regulation of mammalian physiology through the modulation of growth factor 
availability and signalling complex formation [47], making it ideally suited for use in 
growth factor augmentation strategies. In fact, our group has already demonstrated the 
feasibility of its use in a number of tissue repair approaches [23, 48], suggesting that 
the use of HS can be extended to a range of tissues, once a target growth factor has 
been identified. The critical role played by TGF-β1 throughout the wound-healing 
process makes it a prime candidate for the development of an HS-based therapy [33]. 
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1.3. Transforming growth factor-β1 (TGF-β1) 
1.3.1. Structure, synthesis and activation 
TGF-β1 is a homodimeric protein that is synthesised as a 390 amino acid (aa) 
preproprotein. The preproprotein consist of a 29 aa signal peptide, a 249 aa latency-
associated peptide (LAP) and the 112 aa TGF-β1 monomer (Fig. 1.1) [49]. During 
synthesis and processing, the signal peptide gets cleaved, disulphide bonds are formed 
between two monomers and LAP is cleaved from TGF-β1. Active TGF-β1 is a 25 
kDa homodimer that possesses 1 inter-chain and 4 intra-chain disulphide bonds (Fig. 
1.2) [50], while the LAP homodimer possesses 2 inter-chain disulphide bonds [51]. 
Both LAP and TGF-β1 then re-associate non-covalently to form latent TGF-β1 
(LTGF-β1), also known as the small latent complex (SLC), which is an inactive form 
of TGF-β1 (Fig. 1.3). For the majority of cell types so far studied, the SLC is released 
after covalently binding to one of four latent TGF-β1-binding proteins (LTBPs), so 
forming the large latent complex (LLC) [42, 52]. The LTBPs push latent TGF-β1 into 
the extracellular matrix (ECM) by interacting with a variety of adhesive proteins [53], 
so creating deposits of latent TGF-β1 that can be made available upon cell-mediated 
activation. 
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FIGURE 1.1. TGF-β1 synthesis. TGF-β1 is synthesised as a 390 amino acid 
preproprotein containing a signal peptide (S), a latency-associated peptide (LAP) and 
TGF-β1 itself. After translation, the signal peptide is cleaved, disulphide bonds are 
formed between the two monomers and then LAP is cleaved from TGF-β1. LAP and 
TGF-β1 then re-associate non-covalently to form latent TGF-β1 (LTGF-β1), also 
known as the small latent complex (SLC). Disulphide bonds are coloured yellow. 
 
 
FIGURE 1.2. The 3-dimensional structure of TGF-β1 (PDB: 1KLC [50]). The 
individual monomers are coloured orange and grey respectively. (A) Ribbon diagram 
of the TGF-β1 homodimer. (B) Corresponding molecular surface. The figures were 
prepared using PyMOL. 
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Although the LAP has a structure considered to be stable, two regions of the 
molecule can be folded [51] in such a way that it traps TGF-β1 in the SLC (Fig. 1.3). 
When the conformations of these regions are mechanically forced fully open, by 
integrin αV binding to an RGD sequence within LAP, active TGF-β1 is released from 
the SLC [54]. This simultaneous unfolding of both domains, an all-or-nothing snap 
mechanism necessary for full TGF-β1 release, is possible only when LAP is bound to 
one of the LTBPs. 
 
 
FIGURE 1.3. The 3-dimensional structure of latent TGF-β1 (PDB: 3RJR [51]). (A) 
Ribbon diagram of LTGF-β1 demonstrating how the latency associate peptide (LAP) 
(beige) wraps around the TGF-β1 homodimer (orange and grey). (B) Bottom view of 
LTGF-β1. (C) Molecular surface of (B). The figures were prepared using PyMOL. 
 
1.3.2. TGF-β1 signalling 
 Upon activation, the liberated TGF-β1 homodimer is able to bind to the TGF-β 
type II receptor (TβRII) dimer, which in turn recruits the TGF-β type I receptor 
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(TβRI) dimer to form a heteromeric complex [55]. The formation of this complex 
activates the serine/threonine kinase activity of TβRI, which then phosphorylates the 
receptor-activated SMADS – SMAD2 and SMAD3. Phosphorylation of these 
SMADs enables their formation of heterodimers with SMAD4 and subsequent 
translocation into the nucleus. Once there, the heterodimers, in conjunction with a 
number of other factors, are able to activate or inhibit TGF-β1 target gene 
transcription (Fig. 1.4) [56]. A third receptor, known as betaglycan or TGF-β type III 
receptor (TβRIII), is a cell surface proteoglycan that has been shown to bind to TGF-
β1 via its protein core [57], though its effects appear to be mediated through TβRI 
[58]. 
 
FIGURE 1.4. The TGF-β1 signalling pathway. TGF-β1 first binds to the TGF-β type 
II receptor (TβRII) dimer, which then recruits the TGF-β type I receptor (TβRI) dimer 
to form a heteromeric complex [55]. TGFβRI is then able to phosphorylate SMAD2 
and SMAD3, which associated with SMAD4 and migrates into the nucleus to initiate 
TGF-β1 target gene transcription. P – Phosphate group. 
                                                                 30 
CONFIDENTIAL 
 Apart from signalling via the SMADs, TGF-β1 has also been shown to be able 
to signal, albeit in an indirect fashion, via the mitogen-activated protein kinase 
(MAPK) pathway [59]. Through this pathway, TGF-β1 is able to indirectly participate 
in a range of biological processes that include cellular migration, proliferation, 
differentiation, matrix formation, apoptosis and even epithelial to mesenchymal 
transition [60]. These non-SMAD or “non-canonical” pathways have been shown to 
cross-talk with the canonical SMAD pathway [61, 62], which allows their reciprocal 
regulation of each other, and explains the diverse effects of TGF-β1. However, it 
should be noted that the effects of TGF-β1 are highly dependent on cell type and 
dosage. 
 Given the myriad roles played by this growth factor, its potency and its 
relatively simplistic canonical signalling pathway, it is unsurprising that TGF-β1 is 
tightly regulated at the protein level. As described earlier, TGF-β1 is produced in an 
inactive form and sequestered in the ECM via the LTBPs. Free TGF-β1 is rapidly 
inactivated and cleared in vivo by its binding to α2-macroglobulin (α2M) and 
transported to the liver [41]. Additionally, the ability of TGF-β1, LAP and LTBPs to 
bind to heparin/HS adds another level of complexity to its regulation [63-65]. 
Together these systems produce a very intricate regulatory network. 
1.3.3. Interaction with heparin 
 The ability of TGF-β1 to bind to heparin was first reported by McCaffrey et 
al. [41] who subsequently identified its heparin-binding site [66]. This identification 
was based on sequence homology with the known, contiguous heparin-binding motifs 
in FGF: -X-B-B-B-X-X-B-X-X- or -X-B-B-X-B-X-X- (where X is any neutral or 
acidic amino acid and B is a basic residue) [67]. McCaffrey et al. also reported the 
existence of a third motif in TGF-β1: -X-B-X-X-B-X-X-B-X-X-B-X- [66]. Based on 
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this data, the subsequent sequence alignment analysis by Lyon et al. proposed that 
lysine 26 (K26 in the mature TGF-β1 monomer or K304 in the full 390 aa TGF-β1 
protein sequence) was critical for heparin binding in TGF-β1 and β2, but not the β3 
isoform [68]. The model proposed for the interaction of heparin/HS and TGF-β1 sees 
the HS chain spanning the length of the TGF-β1 homodimer, with the N-sulphated 
(NS) domains of the chain interacting with the K26 on either protein monomer (Fig. 
1.5). 
 
FIGURE 1.5. Model for TGF-β1-heparin/HS interactions as proposed by Lyon et 
al.[68]. In this model, the N-sulphated domains (grey) of an HS chain are postulated 
to interact with the lysine 26 residue on each TGF-β1 monomer. Image reproduced 
with permission from Lyon et al. 
 
 While it is now widely accepted that heparin is able to bind TGF-β1, the 
effects of this interaction appear conflicting. Some have reported the serum dependent 
potentiating effects of this interaction [41, 68, 69], while others have reported 
inhibitory effects [70, 71]. Given the cell-type dependent nature of TGF-β1 signalling, 
it is entirely possible that the effects of heparin binding are also context-dependent. It 
is thus conceivable that in some situations the effects of this interaction could be 
leveraged to influence cell behaviour. 
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1.3.4. Physiological roles in wound healing 
 Physiologically, TGF-β1 is intimately involved in the wound healing response, 
though its effects are highly dependent on the cellular context. In the wound site, it 
acts as a chemo-attractant for fibroblasts and a host of immune cells. The fibroblast 
response to TGF-β1 stimulation involves their proliferation and differentiation into 
myofibroblasts, and the subsequent secretion of ECM proteins to aid wound closure 
[72, 73]. Similarly, the role of TGF-β1 during the immune response associated with 
wound healing involves the recruitment and activation of neutrophils, T cells and 
monocytes. Upon their arrival, local temporally modulated TGF-β1 concentrations 
[74] serve to either activate or inhibit the response of immune cells [75]. The early 
effects of TGF-β1 on immune cells include the activation of monocytes to increase 
cytokine production, including TGF-β1, the proliferation of infiltrating cells and 
establishment of a positive feedback mechanism to maintain its local expression. 
Subsequently, TGF-β1 acts to inhibit the proliferation of T cells and B cells in order 
to reign in the local immune response [76]. Through its combined effect on these 
cells, TGF-β1 drives the closure of the wound via the production of granulation tissue 
and modulation of the local inflammatory and immune response. However, the 
sustained production or delayed termination of the TGF-β1 signal has been linked to 
the development of tissue fibrosis [75, 77]. Whether this is a direct result of TGF-β1’s 
action on the production of ECM or a secondary effect arising from its influence on 
immune cells remains to be determined. 
1.3.5. Physiological roles in chondrogenesis 
 Despite its differing effects on cell proliferation and inflammation, TGF-β1 
has been consistently shown to induce the production and deposition of ECM 
components [78]. It is therefore unsurprising to see that TGF-β1 plays a central role in 
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the development and maintenance of cartilage [79-81]. TGF-β1 signalling is able to 
drive the commitment to, and subsequent differentiation of mesenchymal stem cells 
(MSCs) down the chondrogenic lineage [82], through the expression of TGF-β1 target 
genes like SOX9 [83], type II collagen, aggrecan and cartilage oligomeric matrix 
protein (COMP) (Fig. 1.6) [84].  
 
FIGURE 1.6. The chondrogenic commitment and differentiation of MSCs. 
Undifferentiated MSCs commit to the osteochondroprogenitor lineage when 
stimulated with TGF-β1, which initiates the expression of SOX9, the master regulator 
of the chondrogenic phenotype. These signals then stimulate the subsequent 
condensation and differentiation of MSCs towards the chondrogenic phenotype and 
the expression of chondrogenic markers like COMP, Col2α1 and Aggrecan, while 
inhibiting the expression of Col10α1, a marker of chondrocyte hypertrophy. 
 
As well as its central role in the generation and maintenance of cartilage, 
dysregulation of TGF-β1 has been implicated in the formation of osteoarthritis [85-
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87]. This is probably a result of the combination of the age-related changes in 
sensitivity to TGF-β1 [88-90] and altered TGF-β1-induced immune responses [91]. 
Collectively, these reports highlight the pervasiveness of TGF-β1 signalling in vivo 
and the technical tightrope that needs to be tread in the regulation of its activity, as 
falling off this rope may lead to the development of cancer [92, 93]. 
1.3.6. Therapeutic potential 
 The involvement of TGF-β1 in a vast spectrum of physiological processes has 
made the control of its regulation and signalling of considerable clinical interest. 
Research has delved into techniques for both enhancing and inhibiting its effects to 
achieve desirable clinical outcomes. Inhibition of its activity has been explored as a 
therapeutic strategy in the treatment and management of cancer [94], osteoarthritis 
[95] and fibrotic diseases [75].  
Conversely, the enhancement and potentiation of its effects have been 
examined for their potential in enhancing wound healing and tissue repair. Nall et al. 
have demonstrated that application of exogenous TGF-β1 improved wound healing 
and survival in rats after irradiation [96]. Separately, a mutant form of TGF-β3 that 
was unable to bind to LAP was shown to reduce markers for scar formation in a 
mouse model for scarring [97]. Activation of the TGF-β signalling pathway by 
erythropoietin to improve skin healing [98] further validates the therapeutic potential 
of TGF-β1 signalling enhancement for wound healing. In cartilage repair and tissue 
engineering techniques, the beneficial effects of TGF-β1 administration have also 
been widely reported [11, 81, 99]. Current research continues to explore the use of 
exogenously applied TGF-β to enhance chondrogenesis [12, 15, 100]. 
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While these results are encouraging, the eventual use of exogenously applied 
TGF-β1 will need to be weighed against the potential risk of side effects, and/or 
complications that may arise for reasons previously discussed. Developmental 
therapies will need to grapple with the challenges of minimising the diffusion of the 
growth factor from the site of delivery, the minimisation of growth factor clearance 
and/or inactivation, and the management of the temporal release of the administered 
dose. 
 
1.4. Heparan sulphate (HS) 
 Heparan sulphate (HS) is a member of the glycosaminoglycan (GAG) class of 
polysaccharides. This family of polysaccharides is characterised by their repeating 
disaccharide backbone units that combine to form linear, unbranched structures; they 
comprise hyaluronic acid (HA), chondroitin sulphate (CS), dermatan sulphate (CS), 
keratan sulphate (KS) and HS. GAGs are distinguished from each other based on the 
nature of the repeating disaccharide building block used for their synthesis - HA is 
composed of repeating units of glucuronic acid (GlcA) and N-acetylglucosamine 
(GlcNAc); CS and DS are composed of either GlcA or iduronic acid (IdoA) and N-
acetylgalactosamine (GalNAc); KS is composed of repeating galactose (Gal) and 
GlcNAc units; and HS is composed of either GlcA or IdoA and GlcNAc units – and 
the location and concentration of sulphate groups along their chains (Fig. 1.7). All 
GAGs are variably sulphated along the length of their chains, with the exception of 
HA, which is the only GAG to remain unsulphated. Collectively, these differences in 
disaccharide composition and sulphation lead to enormous structural variation 
between and within each class of GAGs. 
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FIGURE 1.7. Representative GAG structures. The basic repeating disaccharide units 
of several GAG family members. R = H or SO3
-. R’ = SO3
-
 or Acetyl. Image adapted 
from http://chemistry.tutorvista.com/organic-chemistry/glycosaminoglycans.html. 
 
Often found attached to protein cores to form proteoglycans (Fig. 1.8), GAGs 
are expressed nearly ubiquitously in the body. Their polyanionic nature, which results 
from their variable sulphation, enables them to perform myriad roles, which include 
the organisation of ECM components, the establishment and maintenance of 
morphogen gradients, and the sequestration and regulation of cell signalling 
molecules [101]. The importance of GAGs in the development and maintenance of 
tissue environments is underscored by the diseases that arise from dysregulation of 
GAG production and turnover, such as the mucopolysaccharidoses [102, 103]. 
Additionally, the informational content of GAGs that arises as a result of their 
heterogeneity, both in size, structure and sulphation content [104, 105], suggests that 
an improved understanding of these molecules would in turn advance our 
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understanding of developmental processes, and better guide the development of tissue 
repair therapies. In this section the synthesis, structure and functions of HS will be 
examined for clues as to its therapeutic potential. 
 
 
FIGURE 1.8. Proteoglycan structures. Proteoglycans consist of a protein core 
(brown) and one or more covalently attached GAG chains. Such chains may be either 
heparan sulphate (blue) or chondroitin/dermatan sulphate (yellow). Cell-surface 
proteoglycans may be either glycosylphosphatidylinositol (GPI)-anchored or span the 
membrane, while ECM proteoglycans are usually secreted. Image reproduced with 
permission from [101]. Copyright held by The Consortium of Glycobiology Editors, 
La Jolla, California. 
 
1.4.1. HS structure and synthesis 
 HS polysaccharides are produced as a copolymer of GlcA and GlcNAc units, 
which then undergo extensive modification reactions in the Golgi before being 
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released by the cell. HS synthesis begins with the attachment of an O-linked 
oligosaccharide linker to a serine/threonine residue of a core protein. This is followed 
by the addition of alternating units of GlcA and GlcNAc, and then the seemingly 
random deacetylation and N-sulphation of GlcNAc residues along the nascent chain 
to form N-sulphoglucosamine (GlcNS). Epimerisation of GlcA to IdoA by GlcA C5 
epimerase then occurs for residues immediately adjacent to GlcNS residues. After 
which a series of O-sulfotransferases catalyse the addition of 2-O- and 6-O-sulphate 
groups to the IdoA and N-sulpho glucosamine residues, respectively (Fig. 1.9). In 
certain situations, a 3-O-sulphate can also be added to IdoA units.  
The inability of these enzyme-catalysed modification reactions to run to 
completion leads to the development of variably sulphated tracts or domains along the 
HS chain. These domains can be highly sulphated (N-sulphated or NS-domains), 
unsulphated (N-acetyl or NA-domains) or a mixture of the two (NA/NS-domains). 
Together with the non-template nature of HS synthesis, which results in the 
production of polysaccharide chains that can range in size from 20-100 kDa [106], 
this variable sulphation of HS produces a hyper variable pool of polysaccharides in 
vivo that will vary between tissue and genders [66, 107, 108]. 
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FIGURE 1.9. HS synthesis. The synthesis of HS involves the sequential addition of 
N-acetylglucosamine (GlcNAc) and glucuronic acid (GlcA) residues. A series of 
modification reactions, which include sulphation and epimerisation of GlcA to 
iduronic acid (IdoA), also occur. Both the polymerisation and modification reactions 
are believed to occur simultaneously. UDP – Uridine diphosphate; PAPS – 3’-
phosphoadenyl-5’-phosphosulphate. Image reproduced with permission from [101]. 
Copyright held by The Consortium of Glycobiology Editors, La Jolla, California. 
 
1.4.2. Heparin – a hypersulphated form of HS 
 Heparin is a hypersulphated form of HS that is synthesised exclusively in 
connective-tissue-type mast cells [109]. Unlike HS, which possesses alternating NS 
and NA domains, heparin is essentially a continuous NS-domain and is therefore less 
heterogeneous than HS (Table 1.1). Additionally, heparin possesses the rare 3-O-
sulfation substitution of glucosamine, that is rarely seen in HS, which enables its 
binding to antithrombin and confers the anticoagulant activity for which it is clinically 
renowned [110]. As a result of its structural similarity and reduced heterogeneity 
                                                                 40 
CONFIDENTIAL 
relative to HS, as well as its plentiful supply at low cost, heparin is often employed as 
an analogue for HS in the study of HS-HS-binding protein (HSBP) interactions. 
TABLE 1.1. Major differences between heparin and HS. Table reproduced with 
permission from [101]. Copyright held by The Consortium of Glycobiology Editors, 
La Jolla, California. 
Characteristics HS Heparin 
Size 10-70 kDa 7-20 kDa 
Sulphate/hexosamine ratio 0.8-1.8 1.8-2.6 
GlcNSO3 40-60% ≥80% 
IdoA 30-50% ≥70% 
Binding to antithrombin 0-0.3% ~30% 
Site of synthesis Virtually all cells Connective tissue-type mast 
cells 
 
1.4.3. HS-HSBP interactions 
 One of the primary outcomes of the hypervariability present in HS is its 
resulting ability to interact with over 300 different proteins, collectively known as the 
heparan interactome or heparanome [25]. These interactions are primarily electrostatic 
in nature, where the negatively charged sulphate groups of HS/heparin interact with 
the positively charged amino acid residues in proteins [106]. Compared to this, the 
contribution of hydrogen bonding, van der Waals forces and hydrophobic clustering 
to the interaction of the HS polysaccharide with proteins is comparatively minor [67, 
111-113]. The specificity of these HS-HSBP interactions is largely determined by the 
local arrangement of sulphate groups within NS- and NS/NA-domains of the HS 
chain (Fig. 1.10), creating a ‘sulphation code’ for molecular recognition [105, 114, 
115], albeit the code in most instances is far from being “lock-in-key” in the manner 
of proteins [106], having a much more relaxed set of activation motifs. Such 
configurations are particularly suited as medium affinity co-receptors [116]. 
While this code has come to be seen as the lynchpin of the heparanome, the 
means to decipher it have left much to be desired. Unlike nucleic acid and proteins, 
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the sequencing of HS is more technically challenging due to the labile nature of the 
sulphate modifications on the chain, and the difficulty in separating isomeric HS 
chains [117]. Also, techniques for the sequencing of HS oligosaccharides are still in 
their infancy [117-119], so the ability to sequence a full HS chain is likely to remain a 
distant goal for now. Until then, the interrogation of HS-HSBP interactions will 
continue to rely on the use of structurally defined oligosaccharide. Most studies rely 
on the use of heparin, heparin-derived oligosaccharides, chemically desulphated 
heparin or HS derived from an arbitrary source, like porcine mucosa. While 
informative, the data provided by these oligosaccharides is unable to provide the 
desired ‘atomic-level resolution’, due to the assumptions that have to be made when 
using heparin-derived oligosaccharides in place of HS – that the arrangement of 
sulphate groups in HS is present or similar to those in heparin, and that groups that are 
not involved in binding will not interfere with the interaction [120]. The development 
of chemoenzymatic methods for the synthesis of more structurally defined 
oligosaccharide should eventually help to overcome these hurdles [121-123]. 
Techniques for identifying heparin-binding sites on proteins are more 
developed, though still subject to the same assumptions made when using heparin in 
place of HS. Ori et al. have developed a selective labelling technique for identifying 
heparin-binding sites on native proteins, termed the ‘Protect and label’ approach 
[124]. By leveraging the sensitivity of modern mass spectrometry (MS) techniques, 
this approach allows the accurate identification of individual lysines residues that 
directly interact with heparin. While the n-hydroxysuccinimide (NHS)-based 
chemistry used in the technique precludes the identification of arginines, one can still 
make inferences from the data obtained. 
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FIGURE 1.10. HS chain structure. HS chains consist of various domains that vary 
based on the extent of their sulphation and epimerisation. The organisation and 
structure of the domain determines the ligand(s) that the domain will be able to bind, 
for example, FGFs and antithrombin. NS – N-sulphated domain; NA – N-acetylated 
domain; NA/NS – variably sulphated domain. Image reproduced with permission 
from [101]. Copyright held by The Consortium of Glycobiology Editors, La Jolla, 
California. 
 
An alternative approach would be the site-directed mutagenesis of predicted 
heparin-binding residues identified based on sequence homology with the heparin-
binding motifs of FGF-2 and TGF-β1 [66, 67]. While this approach would provide 
robust data, the varied nature of heparin-binding sites might entail the generation of 
significant numbers of protein mutants to sufficiently examine all possible 
permutations. 
The use of computational modelling of HS-HSBP interactions could be used 
to achieve the desired ‘atomic-level resolution’ and overcome the need to use heparin 
in place of HS [112, 125]. In fact, a computational approach has been developed for 
deciphering the organisation of GAGs [126]. However, such methods are limited by 
the accuracy of their algorithms and the availability of protein structures [106].  
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1.4.4. Physiological roles of HS in growth factor modulation 
 Physiologically, HS, in the form of HS proteoglycans (HSPGs), is involved in 
a range of processes at both the cell surface and within the ECM, as reviewed by 
Bishop et al. (Fig. 1.11) [47]. At the cell surface, HS is well-known for its role in 
catalysing the formation of ligand-receptor signalling complexes, most notably those 
involved in FGF2 signalling [127-129]. Cell surface HS also aids in the transport and 
presentation of chemokines across cells, and the adhesion of the cell to ECM 
components. HSPGs and HS chains that get released from the cell surface through 
proteolytic or heparanase cleavage, respectively, can bind to and protect or prevent 
the clearance of local growth factors and chemokines [69].  
 
FIGURE 1.11. Physiological roles of HS. As part of an HSPG, HS can function as a 
co-receptor for growth factors and their receptors, which can be present on either the 
same cell (a) or an adjacent one (b). They can also be used to present chemokines 
across cells (c,d). Enzymatic cleavage leads to the shedding/release of HSPGs from 
the cell surface (e) or HS chains (f), which liberates bound ligands. Endocytosis 
actively takes up cell surface HSPGs (g) for recycling or degradation in lysosomes 
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(h). HSPGs also aid cell adhesion to the ECM (i) and form links to the cytoskeleton 
(j). Secreted HSPGs facilitate the formation of organised ECMs that form 
physiological barriers (k) and sequester growth factors and morphogens for 
subsequent release (l). Serglycin, an HSPG carrying heparin chains, is packaged into 
the secretory granules of haematopoetic cells (m). Some experiments also suggest that 
HS chains may exist in the nucleus, though their function remains to be elucidated (n). 
Image reproduced with permission from [47].  
Within the ECM, HS serves as a storage depot for growth factors and 
chemokines that get released during tissue injury to initiate the healing response. The 
abundance of binding motifs for each protein within the ECM HS determines their 
spatial distribution and is critical for the establishment of morphogen gradients [130, 
131]. Such gradients have been shown to significantly influence the growth and 
migration of cells, including neurons [115, 132]. HS and HSPGs have also been 
shown to play roles in the formation and maintenance of physiological barriers [133]. 
Most knowledge about the role of HS in facilitating the formation of ligand-
receptor signalling complexes has been obtained from the study of the stereotypical 
heparin-binding protein, FGF2. The resolution of the crystal structure of a 2:2:2 
FGF2-FGF receptor 1 (FGFR1)-heparin complex was instrumental in the 
development of the “symmetrical model” for the formation of the multimeric complex 
[128]. In this model, heparin is proposed to interact, via its non-reducing ends, with 
both FGF2 and FGFR1 to form a stable 1:1:1 complex. This complex then recruits a 
second, identical, complex through direct FGFR-FGFR contacts, which then initiates 
the FGF2 signalling cascade (Fig. 1.12A). An alternative “asymmetric model” has 
also been proposed, where the signalling complex arises from a 2:2:1 ratio of 
FGF1:FGFR2:heparin [134, 135]. Here the signalling complex is formed around a 
single heparin chain that bridges two FGF-FGFR half-complexes (Fig. 1.12B). 
Separately, it has been proposed that the formation of the FGF-FGFR dimer creates a 
heparin/HS-binding ‘protein canyon’ within the structure that possesses an HS 
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specificity that is distinct from that of FGF and FGFR on their own [136]. Most 
recently, Goodger et al. have reported that the length of the heparin saccharide 
determines the model of ternary signalling complex formation that is adopted [137]. 
While this continues to be the focus of intense research, it remains to be seen if this 
system of heparin/HS-mediated growth factor signalling is representative of other 
growth factor families, or unique to the FGFs.  
 
FIGURE 1.12. The role of heparin/HS in FGF-2 signalling. (A) The crystal structure 
of FGF2 (yellow) in complex with FGF-receptor-1 (FGFR1, red) and a heparin 
oligosaccharide (green), showing how in the “symmetrical model”, heparin aids in the 
formation of the multimeric, 2:2:2 FGF2-FGFR1-heparin signalling complex (PDB: 
1FQ9 [128]). (B) The ribbon diagram (left) and corresponding molecular surface 
(right) of the crystal structure of FGF1 (blue) in complex with FGFR2 (orange) and 
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heparin (green), showing the “asymmetric model” for the 2:2:1 FGF1-FGFR2-heparin 
complex (PDB: 1E0O [134]). The figures were prepared using PyMOL. 
 
1.4.5. Therapeutic potential of HS 
 Since its initial discovery, heparin has seen widespread clinical use as an 
anticoagulant [110]. Its ability to promiscuously bind a range of clinically relevant 
growth factors has also led to it use as a carrier for such growth factors in a number of 
tissue engineering approaches [6, 24, 100, 138]. However, the use of heparin beyond 
its current anticoagulant role is unlikely to see widespread adoption because of its risk 
of initiating thrombocytopenia [139], and its non-selective protein-binding nature. 
Attempts have been made to overcome these challenges through the use of smaller 
and/or chemically modified heparin derivatives that possess reduced or absent 
anticoagulant properties [140-142]. However, this prompts the question of why one 
would want to search for a heparin mimic of HS, when it might be easier and more 
logical to go straight to HS itself. 
 Unlike heparin, HS does not possess the 3-O-sulphation present in heparin and 
thus naturally lacks the accompanying anticoagulant activity. Additionally, unlike 
heparin, HS chains possess a degree of relative selectivity in protein binding as a 
result of their ‘sulphation-code’. The highly heterogeneous nature of HS and its 
omnipresence in all vertebrates means that it is unlikely to possess much 
immunogenicity, as evidenced by the immense difficulty faced in generating anti-HS 
antibodies [143]. When coupled with the numerous roles played by HS in vivo, and its 
stability over extended periods [26], it would appear that there is a significant, 
untapped, potential for the use of this polysaccharide clinically, particularly in 
therapies requiring exogenous growth factor administration, where the use of an 
engineered HS variant may reduce or negate the need for exogenous growth factors. 
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1.5. Thesis outline 
1.5.1. Motivation 
 Articular cartilage is an avascular tissue found at the ends of long bones that 
serves to absorb shock and lubricate our joints. However, its avascular nature prevents 
the healing of injuries it sustains, which often leads to chronic joint inflammation and 
further erosion of the cartilage. The central role of TGF-β1 in the development and 
maintenance of normal articular cartilage has made it the prime candidate for the 
development of cartilage repair strategies.  
Numerous studies have examined the use of TGF-β as an adjuvant to drive the 
chondrogenic differentiation of MSCs, either prior to or after their implantation within 
the cartilage defect site [87, 99, 100, 144, 145]. However, these approaches often 
require the use of recombinant TGF-β1 at supraphysiological levels, which poses a 
significant risk of severe side effects both within and outside of the administration site 
[10, 86]. When considered with the age-related decrease in sensitivity to TGF-β1 [88-
90], it becomes apparent that the use of exogenously administered TGF-β1 will not be 
a panacea for cartilage repair. 
The challenge then is to drive the effective differentiation of implanted cells 
used for cartilage repair without the use of exogenous TGF-β1. Studies on the 
endogenous levels of TGF-β1 show that it increases significantly after platelet 
degranulation [146], suggesting that sufficient levels exists in vivo. Separate studies 
have also shown that (1) endogenous levels of TGF-β1 are sufficient to drive cartilage 
repair [18]; and that (2) if given the right cues, endogenous cells can be recruited to 
repair an entire joint [147]. While promising, both these studies still relied on the use 
of either self-assembling peptide nanofibres to sequester endogenous TGF-β1 or 
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exogenous TGF-β3 to promote cell recruitment and differentiation. As such, these 
strategies fail to address the immunological risks of the use of synthetic peptides or 
avoid the supraphysiological dosing of growth factor, respectively. 
Our group has previously shown that the use of affinity-purified HS variants is 
able to promote both bone healing [148] and angiogenesis [149] without the use of 
exogenous growth factors. This thesis will therefore explore the potential of HS to be 
developed and utilised as a therapeutic for cartilage repair. 
1.5.2. Hypothesis and specific aims 
 The overarching aim of this thesis is to develop an HS-based strategy for 
cartilage repair that will either reduce or altogether avoid the need for exogenous 
TGF-β1 administration to promote the chondrogenic differentiation of MSCs in vivo. 
The in situ differentiation of MSCs would avoid the need for lengthy and complicated 
isolation, culture and differentiation procedures and the accompanying increase in 
treatment costs. We hypothesise that the use of an affinity selected sub-fraction of HS 
will be able to potentiate TGF-β1 signalling in MSCs, and thereby improve their 
chondrogenic differentiation and repair of cartilage defects. To this end, we 
specifically aim to: 
1. Examine the structural determinants and constraints in TGF-β1-heparin 
interactions. 
2. Isolate and characterise an affinity purified TGF-β1-binding HS population 
from crude porcine mucosal HS (HS
PM
) preparations. 
3. Determine the ability of the isolated HS fraction (HS16+ve) to promote the 
chondrogenic differentiation of MSCs in vitro and in vivo. 
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CHAPTER 2. EXAMINATION OF TGF-β1-HEPARIN INTERACTIONS 
2.1. Introduction 
In order to develop an HS-based therapeutic approach to cartilage repair, it is 
first necessary to examine and more fully understand the elements that control the 
interaction between TGF-β1 and heparin/HS. Better understanding of these factors 
will provide insight into both the structural requirements and the constraints that 
impinge on the heparin/HS-TGF-β1 interaction, which in turn should help guide the 
design and production of any resulting therapeutic [150]. The interactions of heparin 
with members of the fibroblast growth factor (FGF) family [129, 130, 151-158], the 
bone morphogenetic proteins (BMPs) [23, 112, 159-162], the hedgehogs including 
sonic hedgehog (Shh) [163-165] as well as the vascular endothelial growth factors 
(VEGFs) [166-170] have been extensively studied, and provided some of the crucial 
regulatory elements underpinning these interactions. These include the formation of 
ternary binding complexes, allosterism, and protection from both proteolytic attack 
and specific inhibition. This knowledge has in turn been exploited by our group in the 
development of a number of affinity-selected HS variants for tissue repair [148, 149]. 
Like other members of its structural family, TGF-β1 has been shown to be a 
heparin-binding protein [41, 66, 69] and a model for its interaction with heparin has 
been proposed [68]. However, few groups, if any, have examined the structural 
requirements for this interaction and how they affect TGF-β1 bioactivity. More 
importantly, the heparin-binding domain of TGF-β1 was identified based on the 
heparin-binding consensus sequence determined in FGF-2 [151]. This consensus 
sequence was identified based on a particular congregation of basic residues in the 
primary protein sequence. As such, the approach has neither been able to account for 
the structural differences between TGF-β1 [50] and FGF-2 [171] nor the existence of 
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binding domains that arise from protein folding. There is thus a fundamental need to 
accurately map and verify the heparin-binding domain(s) of TGF-β1 before 
embarking on a study of its interaction with heparin/HS. While it would be preferable 
to map the HS-binding domains of TGF-β1 and focus on the study of TGF-β1-HS 
interactions instead of heparin, the heterogeneous nature of HS presents a range of 
hurdles that the current suite of glycobiology assays is unable to surmount. 
In this chapter we utilise a structural proteomics approach, dubbed “Protect 
and Label” [124], to identify the amino acid residues in TGF-β1 that are involved in 
its binding to glycosaminoglycans. Subsequently, the effects of heparin chain length 
and sulphation density on TGF-β1 binding and bioactivity were investigated with a 
number of molecular and cell biology assays. An updated model for interaction of 
TGF-β1 and heparin/HS and its variation within the TGF-β superfamily is then 
proposed. 
 
2.2. Materials and methods 
2.2.1 Surface plasmon resonance (SPR) 
Internally biotinylated heparin was prepared based on the protocol reported by 
Hernaiz et al. [172]. Briefly, 20 mg of heparin was filter-sterilized (0.22 μm) in 1 mL 
of water and incubated with 8.6 μmol of N-hydroxysuccinimide-biotin (NHS-biotin) 
(Pierce) in 20 μL of dimethyl sulfoxide (DMSO) for 2 h at 4°C. The biotinylated 
heparin was then extensively dialysed (7000 MWCO) to remove unreacted biotin. 
Immobilisation of the biotinylated heparin onto a streptavidin (SA) sensor surface 
(GE Healthcare) was carried out using the in-built immobilisation protocol on the 
Biacore T100 (GE Healthcare) with a targeted immobilisation level of approximately 
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40 response units (RUs), where 1 RU is equivalent to ~1 pg of protein/mm
2
 although 
the equivalent value for heparin has never been determined. HBS-EP running buffer 
(10 mM HEPES, 150 mM NaCl, 3.0 mM EDTA, 0.05% (v/v) Tween 20, pH 7.4) was 
used for the immobilisation. 
 TGF-β1-heparin interactions were effected by preparing a series of TGF-β1 
protein samples, 50 to 800 nM final concentrations, diluted in HBS-EP-0.1 running 
buffer (0.1% instead of 0.05% (v/v) Tween 20). The sample solutions were then 
injected over the heparin-derivatised surface at a flow rate of 30 μL/min for 120 s, 
with HBS-EP-0.1 being subsequently passed over the surface for a further 600 s to 
monitor TGF-β1 dissociation. After dissociation, the sensor surface on the chip was 
regenerated by 2 washes of 2 M NaCl injected at 30 μL/min for 60 s. In control 
experiments, the binding of 200 nM TGF-β1 to the uncoated streptavidin surface was 
~40 RUs, while binding to the heparin-derivatised surface was ~140 RUs. 
Competitive binding experiments were carried out as above, with a final 
concentration of 200 nM TGF-β1 or 25 nM BMP-2 in HBS-EP-0.1 mixed with either 
5 or 10 μg of heparin, heparin derivative or HS fraction, as described in the figure 
legends. For each sugar, injection of TGF-β1 pre-bound with a given dose of sugar 
was alternated with injection of TGF-β1 alone to ensure a stable baseline before 
obtaining readings for the following sample. Responses were measured as a function 
of time (sensogram) at 25°C. In competitive binding assays the maximum binding 
response for each condition was normalised to the response obtained from TGF-β1 
alone. Competitive binding assays were repeated at least twice. 
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2.2.2. Glycosaminoglycan (GAG) ELISA 
To determine the ability of TGF-β1 to bind to sugar, we utilised positively-
charged GAG-binding plates (Iduron, Manchester, UK) as a capture substrate. GAGs 
were passively adsorbed in each well and then challenged with TGF-β1 according to 
the manufacturer's instructions. Briefly, wells were first pre-coated with 5 μg/mL of 
full length heparin, size-fractionated heparin (dp4, 6, 8, 10 and 12 or dp14, 16, 18, 20, 
22 and 24) or selectively desulphated heparin prepared in standard assay buffer (SAB) 
(100 mM NaCl, 50 mM sodium acetate, 0.2% (v/v) Tween 20, pH 7.2), and then 
incubated overnight at room temperature. The plates were next washed carefully three 
times with SAB, blocked with 250 μL of blocking solution (0.4% (w/v) fish skin 
gelatine, Sigma-Aldrich, in SAB) and incubated for 1 h at 37°C. TGF-β1 was then 
dissolved in blocking solution at a concentration of 100, 200, or 400 ng/mL. The 
plates were washed three times with SAB and each dilution of protein (200 μL) was 
dispensed into triplicate wells and incubated for 2 h at 37°C, rinsed with SAB and 
200 μL of 750 ng/mL monoclonal mouse anti-TGF-β1 antibody (MAB2401, R&D 
Systems) added in blocking solution. Plates were then incubated for 1 h at 37°C, 
washed with SAB, and 200 μL of 1 μg/mL polyclonal goat anti-mouse biotinylated 
antibody (ab6788, Abcam) added in blocking solution. Again, plates were incubated 
for 1 h at 37°C, washed with SAB, and 200 μL of 220 ng/mL ExtrAvidin AP (Sigma-
Aldrich) was added in blocking solution, incubated for 30 min at 37°C, and then 
rinsed with SAB. Finally, 200 μL of development reagent (SigmaFAST p-Nitrophenyl 
phosphate, Sigma-Aldrich) was added, incubated at 37°C for 40 min and read at 
405 nm within 1 h. 
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2.2.3. Structural proteomics - “Protect and label” technique 
The heparin-binding sites on TGF-β1 were identified by the “Protect and 
Label” approach, as described by Ori et al. for FGF-2 [124], except that 1 nmol of 
TGF-β1 protein and 0.1% (w/v) RapiGestTM SF Surfactant (Waters Corporation, MA, 
USA) was used to elute the protein from the mini-column, because 2M NaCl proved 
inadequate. Digested and biotinylated peptides were purified on a C18 ZipTip (Merck 
Millipore, MA, USA) and then analysed by tandem mass spectrometry (MS/MS). Up 
to 2 µg of the biotinylated peptides were injected into an LTQ Velos instrument 
(Thermo Fisher Scientific, MA, USA) using an EASY-nLC (Proxeon, Thermo Fisher 
Scientific). Peptides were separated on a PicoFrit
TM
 column (HALO, C18, 90 Å, 2.7 
µm, 75 μm (internal diameter) x 100 mm length) (New Objectives, MA, USA) using a 
60 min linear gradient (2–40% (v/v) acetonitrile in 0.1% formic acid). Data 
acquisition was performed using a TOP-10 strategy where survey MS scans were 
acquired in the dual pressure linear ion trap; MS scans ranged from 310 to 1400 m/z, 
with an automatic gain control (AGC) target of 3 x 10
4
 and a maximum injection time 
of 10 ms. The 10 most intense ions with an ion intensity above 1000 and a charge 
state excluding one were sequentially isolated to a maximum AGC target value of 4 x 
10
4
 for a maximal 100 ms and fragmented by Collision Induced Dissociation (CID) 
using a normalised collision energy of 30%. A dynamic exclusion list was applied 
using an exclusion list size of 500, one repeat count, repeat duration of 45 s, exclusion 
duration of 30 s as well as a mass width of 1.0 low and 1.5 high. Expiration was 
disabled. 
Data analysis was performed using Mascot search (version 2.3, Matrix 
Science) using the ipi.HUMAN.v3.86.decoy database (183,568 sequences) and 
applying the following parameters: digest, chymotrypsin (FWYL/P); maximum 
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missed cleavages, 2; Fixed modifications,  carbamidomethyl (Cys); possible 
modifications, acetyl (Lys), acetyl (Protein N-term), biotin (Lys), oxidation (Met); 
parental ion tolerance, 2 Da; fragment ion tolerance, 0.8 Da. Biotinylated peptides 
with a Mascot score higher than 20 were manually validated. 
2.2.4. Human MSC (hMSC) isolation, characterisation and cell culture 
Primary hMSCs were isolated from commercially available bone marrow 
mononuclear cells (Lonza, MD, USA) of a young healthy adult human donor by 
plastic adherence and characterized as previously described [1, 173]. The adherent 
cells were maintained in a basal medium consisting of DMEM-low glucose (DMEM-
LG) (1000 mg/L) supplemented with 10% foetal calf serum, 100 U/mL penicillin, 100 
μg/mL streptomycin and 2 mM L-glutamine, and cultured under standard conditions 
at 37°C and 5% CO2 in a humidified atmosphere. Medium replacement was every 
three days. Cells were detached with 0.125% (v/v) trypsin/Versene solution with 
EDTA (pH 7.0) (Gibco, Life Technologies) upon reaching 75–80% confluence, and 
re-plated at a density of 3,000 cells/cm
2
 under the same culture conditions. All 
experiments were carried out with cells at either passage 4 or 5. 
2.2.5. Chondrogenic differentiation of human mesenchymal stem cells (hMSCs) 
Chondrogenic differentiation was carried out using a modified micromass 
culture system as described by Zhang et al. [174]. Briefly, passage 4 hMSCs were 
harvested and resuspended in chemically defined chondrogenic media (PT-3003, 
Lonza, MD, USA) at 2 x 107 cells/mL. Droplets of 12.5 μL were then seeded into the 
middle of each well in a 24-well plate and left to adhere at 37°C for 2 h, after which, 
500 μL of chondrogenic media supplemented with either 1 or 10 ng/mL of TGF-β1 
(100-21C, PeproTech) alone or with either 5 or 10 μg/mL of heparin (Sigma–
Aldrich), porcine mucosal HS (HS
PM
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added to each well. The cell aggregates in each droplet coalesced into spherical 
masses after 24 h. Media was changed every 3 days and the micromasses harvested on 
days 3, 7, 14 and 21. Alcian blue staining of paraffin embedded sections was 
quantified using ImageJ. Brifely, the threshold colour was set as white and the colour 
space was set to RGB. The red and green pass filters were deactivated and the blue 
pass filter was adjusted to include all values between 0 and 255. Images of the 
sections were selected using the polygon tool and the mean grey value measured for 
each section. 
2.2.6. Cell lysis and western blotting 
Human MSCs were cultured in 6-well plates in basal medium for 24 h at a 
density of 10,000 cells/cm
2
. TGF-β1 treatments were then prepared at either 1 ng/mL 
or 5 ng/mL alone or in the presence of either 10 μg/mL or 40 μg/mL of full length 







, and incubated at room temperature 
for 10 min before being added to the cells. Latent TGF-β1 (LTGF-β1) treatments 
were similarly prepared at 3.3 ng/mL alone or with 10 μg/mL of the various GAGs 
described above. For inhibitor studies, the cells were pre-treated for 30 min with 10 
μM SB431542 (Sigma-Aldrich) or DMSO before treatment with TGF-β1. The cells 
were then subjected to the various TGF-β1 treatments for 6, 12, 24 or 48 h and lysed 
in 2x Laemmli buffer (Sigma-Aldrich), before being resolved on a 4-12% (w/v 
gradient) SDS-PAGE gel. Samples were then immunoblotted with antibodies against 
SMAD2/3 (#3102, Cell Signaling), phosphorylated SMAD2 (pSMAD2) (#3108, Cell 
Signaling), phosphorylated SMAD3 (pSMAD3) (#9520, Cell Signaling) and actin 
(MAB1501R, Millipore). Densitometry was carried out using either Quantity One 
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software (version 4.6.6, Bio-Rad) or Image Studio Lite Ver 4.0 and normalised to 
actin. 
2.2.7. Heparinase treatment of hMSCs 
To assess the influence of endogenous HS on TGF-β1 signalling, hMSCs were 
seeded at a density of 7,500 cells/cm
2
 in 12-well plates in basal medium and allowed 
to attach overnight. A combination of heparinase I, II and III (1.2 mIU/mL of each) 
was then added to the media in each well and incubated for 24 h. The cells were then 
exposed for 6 h to TGF-β1 treatments, prepared at either 1 ng/mL or 5 ng/mL alone or 
pre-incubated for 10 min at room temperature with either 10 μg/mL or 40 μg/mL of 
full length heparin, and then lysed for immunoblotting in 2x Laemmli buffer. 
Treatments were prepared in serum-free medium (DMEM-LG supplemented with 100 
U/mL penicillin, 100 μg/mL streptomycin and 2 mM L-glutamine) to avoid increasing 
the background levels of pSMAD seen when fresh serum is added to cells. 
2.2.8. Immunofluorescence staining of heparinase-digested cells 
 To ensure that the heparinase treatment effectively removed endogenous HS 
chains from hMSCs, cells were seeded in 8-well chamber slides at a density of 3,500 
cells/cm
2
 in basal medium. Cells were allowed to attach overnight before being 
treated with a combination of heparinise I, II and III (1.2 mIU/mL each), added 
directly to each well, for 24 h. Subsequently, cells were fixed in 4% (w/v) 
paraformaldehyde in PBS for 10 min at room temperature, blocked with 3% (w/v) 
bovine serum albumin (BSA) in PBS for 30 min at room temperature and then 
incubated with the anti-HS 10E4 antibody (1:25 dilution in 0.3% (w/v) BSA-PBS) 
(AMS Biotechnology, Abingdon, UK) for 3 h at room temperature. Cells were then 
incubated with an anti-mouse IgM-FITC antibody (1:500 dilution in 0.3% (w/v) BSA-
PBS) (BD Pharmingen
TM
, Becton, Dickinson and Company, NJ, USA) for 45 min at 
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room temperature and the nuclei stained with Hoechst 33342 (2 μg/mL in PBS) (Life 
Technologies) for 10 min at room temperature. Samples were imaged on an Olympus 
IX-81. 
2.2.9. Statistical analysis 
All results were analysed using two-tailed unpaired Student’s t-test assuming 
unequal variances or one-way ANOVA; P values <0.05 were considered significant. 
Significant differences between treatment and relevant control levels are marked with 
a single (*) (P < 0.05), double (**) (P < 0.01), or triple (***) (P < 0.001) asterisk. 
Significant differences between treatments are indicated on the graphs. 
2.3. Results 
2.3.1. Heparin binds to TGF-β1 
 In order to explore the structural requirements and constraints of the heparin-
TGF-β1 interaction, the dose ranges of heparin and TGF-β1 for use in subsequent 
experiments had to be determined. To do so, ~40 RUs of internally biotinylated 
heparin were immobilised onto a streptavidin surface and TGF-β1 samples (50 – 800 
nM) injected over it to determine surface plasmon resonance (SPR) in a Biacore T100 
(Fig 2.1A). The resulting sensograms showed that TGF-β1 was indeed able to bind to 
the heparinised surface in a dose-dependent manner. To rule out the possibility that 
the observed binding was an artefact of the biotinylation of heparin, native heparin 
was also adsorbed onto the surface of GAG-binding plates and bound TGF-β1 
detected via ELISA (Fig. 2.1B). A dose of 5 μg/mL of heparin was used as higher 
doses did not lead to significant increases in signal (Sup. Fig. A1 and unpublished 
data from the lab). Again, TGF-β1 was observed to bind to heparin in a dose-
dependent manner. 
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FIGURE 2.1. Heparin binds to TGF-β1. (A) SPR sensogram showing the change in 
binding response to various concentrations (50 to 800 nM) of injected TGF-β1 over a 
heparin-coated surface. (B) GAG ELISA to determine the ability of TGF-β1 to bind 
to heparin. Error bars represent standard deviation, n = 3. 
 
2.3.2. Identification of TGF-β1 heparin binding sites 
 Having verified that heparin was able to bind to TGF-β1, we next sought to 
identify the residues in TGF-β1 that were involved in this interaction. Previous studies 
that sought to identify putative heparin-binding sites on TGF-β1 did so through the 
identification of heparin-binding motifs present in the contiguous protein sequence 
[66, 68]. However, this approach is unable to identify heparin-binding sites that 
consist of amino acids brought into proximity by protein folding [25].  We therefore 
used the "Protect and Label" approach developed by Ori et al. [124] to identify 
directly those lysine residues most likely to be involved in the binding of TGF-β1 and 
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heparin. Briefly, the technique involves the selective labelling of solvent-exposed 
lysine residues, in a given protein, using n-hydroxysuccinimide (NHS)-based 
chemistry, while it is first bound and then subsequently unbound to heparin (Fig. 
2.2A). This selective labelling enables the identification of lysines that directly 
interact with heparin, and their location in the protein, through tandem mass 
spectrometry (MS/MS) sequencing. During the selective labelling process, samples of 
the protein of interest are taken at several points of the experiment, resolved by SDS-
PAGE and silver stained (Fig. 2.2B). This serves as a quality control step to ensure 
that significant amounts of protein have not been lost at any stage.  
In the case of TGF-β1, no protein was recovered from the first column wash 
(Fig. 2.2B, sample 2), suggesting that either the interaction between TGF-β1 and the 
heparin beads was sufficiently strong to resist a 150 mM NaCl wash, or that the 
maximum binding capacity of the column was greater than the 25 μg of TGF-β1 that 
was loaded.  A small amount of protein was recovered after the protection/acetylation 
step (Sample 3), which indicated that the interaction between TGF-β1 and heparin is 
dynamic. In such an instance, the transient exposure of a heparin-binding lysine to the 
solvent would have led to the acetylation of the residue. If the situation were to be 
repeated across a significant number of all the heparin-binding lysines of the protein, 
the protein would cease to bind heparin and get collected in the column flow through, 
as was the case here. As 2 M NaCl was unable to effectively elute the 
protected/acetylated TGF-β1 from the column, RapiGest, an acid-labile detergent, was 
employed instead (Sample 4) (Sup. Fig. A2). The subsequent concentration, 
labelling/biotinylation and de-salting of the TGF-β1 sample (Samples 5, 6 and 7, 
respectively) led to some loss of sample, but sufficient amounts for chymotryptic 
digest, StrepTactin purification and MS/MS were still recovered. Tandem MS-based 
                                                                 60 
CONFIDENTIAL 
sequencing of the purified peptides identified 11 unique peptides (Table 2.1). The 
chymotrypsin cleavage sites are indicated in Sup. Fig. A3. 
 
FIGURE 2.2. The “Protect and Label” structure proteomics technique. (A) Schematic 
summarising the steps in the “Protect and Label” technique. Note that RapiGest was 
used to elute the “protected” protein instead of 2M NaCl. Figure adapted from Ori et 
al. [124]. (B) Silver stained gel showing the quality control samples of TGF-1 taken 
at the indicated stages of the “Protect and Label” experiment. The TGF-1 
homodimer runs at 25 kDa while the monomer runs at 12.5 kDa. NHS – n-
hydroxysuccinimide, HBS – Heparin-binding site, ACN – Acetonitrile, TFA – 
Trifluoroacetic acid, MS – Mass spectrometry. 
 
Of the 11 peptides identified, 9 contained biotinylated lysines while 2 did not 
(peptides 2 and 11, Table 2.1). As biotinylated lysines were predicted to be involved 
in heparin binding, the identification of peptides 2 and 11 was unexpected, as they 
should not have remained in the StrepTactin-purified sample. However, the sequences 
of both these peptides were found to overlap with those of the other 9 biotinylated 
peptides that had been identified, so the method appeared to be robust. Two pairs of 
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peptides (peptides 4 and 5, and 8 and 9) were found to contain lysines that could be 
both biotinylated and acetylated, which again underlines the dynamic nature of the 
heparin-TGF-β1 interaction. Finally, the MS/MS spectra for peptide 7 contained 
unassigned peaks, so there is a possibility, although minor, that its actual sequence 
may differ from the one listed in Table 2.1. 
TABLE 2.1. Summary of peptides identified by “Protect and Label” structure 
proteomics. Labelled peptides were identified by tandem mass spectrometry and 
analysed by Mascot search Version 2.4 (Matrix Science). Here, a summary of the 
peptides involved in the heparin-binding sites and the labelled position is provided. A 










3 IDFRK(biotin)DLGW 300-308 
4 RK(biotin)DLGWK(acetyl)W 303-310 
5 RK(acetyl)DLGWK(biotin)W 303-310 
6 IHEPK(biotin)GY 311-317 
7 SLDTQYSK(biotin)VL 331-340 
8 YVGRK(biotin)PK(acetyl)VEQL 369-379 








Residues numbered according to Fig. 2.3. 
 
 When mapped onto the full amino acid sequence of TGF-β1, it was found that 
all but 3 of the identified lysines (K291, K338 and K388) were located within the 
previously predicted heparin-binding domain (HBD) of TGF-β1 (Fig. 2.3A) [66, 68]. 
However, K338 has been postulated to be a secondary heparin-binding site in TGF-β1 
[68], so that only K291 and K388 would be novel heparin-binding residues. In the 3-
dimensional solution structure of TGF-β1 (PDB: 1KLC) [50], K291 was found to map 
onto the same surface of the TGF-β1 homodimer as K304, which has been proposed 
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[68] as an essential residue for heparin binding (Fig. 2.3B). However, K388 appears 
to be a “conformationally buried” residue, so its detection is likely due to either the 
unfolding of the protein as a result of exposure to RapiGest, or a conformational 
change in the protein that arises from its binding to sugar. Arginine residues have also 
been reported to play roles in heparin binding [175], and bind to heparin more tightly 
than lysines, due to the intrinsic properties of their side chains [176]. However, the 
nature of the NHS-based chemistry used precludes their labelling and identification. 
Also, our results show that arginines tend to cluster with lysines within the TGF-β1 
protein sequence, so their role in binding heparin can be inferred from our data. 
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FIGURE 2.3. Identification of TGF-β1 heparin-binding sites. (A) The TGF-β1 amino 
acid sequence and position of lysines identified by the “Protect and label” strategy. 
The previously published predicted heparin-binding domain (HBD) of TGF-β1 is 
underlined. Lysines identified with high confidence (*) and medium confidence (^) 
are indicated. (B) The positions of the identified lysines mapped onto the 3-
dimensional structure of TGF-β1 (PDB: 1KLC [50]). The newly identified lysines are 
colored blue and those overlapping with the literature-annotated heparin-binding sites 
are colored green. Top row, ribbon diagram. Bottom row, corresponding molecular 
surface. Residues are only labelled on one of the TGF-β1 monomers. The figures 
were prepared using PyMOL. 
 
2.3.3. Heparin length requirements for TGF-β1 binding 
 We next sought to determine the minimum length of heparin chain required to 
bind TGF-β1. The ability of soluble, size-fractionated (dp4 to dp24) heparin 
fragments to competitively inhibit the binding of TGF-β1 to a heparin-coated SA-chip 
increased in proportion to their length (Fig. 2.4). This increase in TGF-β1 binding 
ability plateaued from dp18 onwards, with the competition reaching levels 
approaching those seen for unfractionated, full-length heparin (Hep). In order to 
validate the findings from these SPR experiments, we also tested these interactions 
with GAG-binding plate assays. The results also indicated that TGF-β1 binding to 
heparin improved as the length of the heparin chain increased from 14 (dp14) to 24 
(dp24) saccharide units (Fig. 2.5). While a weakness of this assay is that the 
electrostatic capture of polysaccharide may obscure or change the conformation of 
binding sites [177], the fact that similar results were obtained in both this and the 
methodologically distinct SPR experiments lends confidence to our conclusion. 
Collectively, the data indicate that TGF-1 binds better to heparin chains that are at 
least 18 saccharides long. 
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FIGURE 2.4. Biacore competition assays to determine heparin length requirements 
for TGF-β1 binding. Representative SPR sensograms showing the changes in binding 
response of 200 nM of TGF-β1 when pre-incubated with either 5 or 10 μg of (A) dp4, 
(B) dp12, (C) dp20 or (D) heparin (Hep) prior to injection. (E) Bar chart depicts the 
ability of the various GAGs to compete for TGF-β1 binding against the heparin-
coated surface. For clarity, the binding response of TGF-1 without any GAG (i.e. 0 
g) is only shown for heparin. Data were normalised to 200 nM TGF-β1 alone. Error 
bars represent standard deviation, n = 3. N.D. – Not detectable. 
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FIGURE 2.5. GAG ELISA to determine heparin length requirements for TGF-β1 
binding. Error bars represent standard deviation, n = 3. 
 
2.3.4. Heparin sulphation requirements for TGF-β1 binding 
 Our next aim was to examine the influence that the various sulphate moieties 
in heparin have over the interaction with TGF-β1. In SPR competition assays with 
soluble chemically-modified heparins, the loss of 2-O sulphate groups from heparin 
(2-O-de) had only minimal effects on its ability to competitively inhibit TGF-β1 
binding to immobilised heparin (Fig. 2.6). The loss of 6-O sulphate groups (6-O-de) 
led to a loss of approximately 40% of TGF-β1’s binding ability, while the loss of N-
sulphate groups (N-de) abrogated heparin’s ability to bind TGF-β1. In contrast, GAG-
binding plate assays demonstrated that the removal of 2-O sulphate groups from 
heparin reduced TGF-β1 binding by about 60% compared to fully sulphated, full-
length heparin (Hep) (Fig. 2.7). The removal of 6-O sulphate reduced TGF-β1’s 
ability by approximately 80% and the lack of N-sulphation again essentially abolished 
TGF-β1 binding. Taken together, the data suggest that N- and 6-O-sulphate groups 
play a more significant role in the TGF-1-heparin interaction than 2-O-sulphate 
groups. 




FIGURE 2.6. Biacore competition assays to determine heparin sulphation 
requirements for TGF-β1 binding. Representative SPR sensograms showing the 
changes in binding response of 200 nM of TGF-β1 when pre-incubated with either 5 
or 10 μg of (A) 2-O-desulphated heparin (2-O-de), (B) 6-O-desulphated heparin (6-O-
de), (C) N-desulphated heparin (N-de) or (D) heparin (Hep) prior to injection. (E) Bar 
chart depicts the ability of the various GAGs to compete for TGF-β1 binding against 
the heparin-coated surface. For clarity, the binding response of TGF-1 without any 
GAG (i.e. 0 g) is only shown for heparin. Data were normalised to 200 nM TGF-β1 
alone. Error bars represent standard deviation, n = 3. 
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FIGURE 2.7. GAG ELISA to determine heparin sulphation requirements for TGF-β1 
binding. Error bars represent standard deviation, n = 3. 
 
2.3.5. Isolation and characterisation of hMSCs 
 In order to examine the biological effects of the heparin-TGF-β1 interaction, it 
was necessary to isolate primary hMSCs. Commercially available bone marrow 
mononuclear cells (Lonza) were purchased and hMSCs isolated via plastic adherence. 
Passage 0 cells were subsequently expanded and frozen in batches of 1x10
6
 cells per 
vial. Cells were screened by FACS for MSC surface marker expression at passage 5 
as described by Dominici et al. [178]. More than 95% of the isolated hMSCs 
expressed CD73, CD90 and CD105 (Fig 2.8), while CD14, CD19, CD34, CD45 and 
HLA-DR were not expressed (Fig 2.9). The isolated cells were also able to 
differentiate into osteoblasts, adipocytes and chondroblasts in vitro, although 
quantification of Alcian blue staining of the pellets showed no significant difference 
between control (Ctrl) and differentiated (Differentiated) groups (Fig 2.10). Thus the 
cells that had been isolated by plastic adherence were deemed to satisfy the minimal 
criteria characteristics of hMSCs. 
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FIGURE 2.8. FACS analysis of isolated hMSCs for positive MSC surface markers. 
Single-colour flow cytometry was performed on passage 5 hMSCs. Scatter plots 
showing the gating of live cells used to measure (A) CD73, (B) CD90 and (C) CD105 
expression. Histograms showing the expression of (D) CD73, (E) CD90 and (F) 
CD105 (blue) compared to isotype controls (red). SSC - Side scatter; FSC – Forward 
scatter; PE – Phycoerythrin. 
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FIGURE 2.9. FACS analysis of isolated hMSCs for negative MSC surface markers. 
Single-colour flow cytometry was performed on passage 5 hMSCs. Scatter plots 
showing the gating of live cells used to measure (A) CD14, (B) CD19, (C) CD34, (G) 
CD45 and (H) HLA-DR expression. Histograms showing the expression of (D) 
CD14, (E) CD19, (F) CD34, (I) CD45 and (J) human leukocyte antigen-DR (HLA-
DR) (blue) compared to isotype controls (red). SSC - Side scatter; FSC – Forward 




FIGURE 2.10. Tri-lineage differentiation of isolated hMSCs. Passage 5 hMSCs were 
differentiated in (A) osteogenic, (B) adipogenic or (C) chondrogenic culture 
conditions for 21 days. Detection of mineralisation in osteogenic cultures, oil droplets 
in adipogenic cultures and GAG production in chondrogenic cultures was carried out 
using alizarin red, oil-red O and alcian blue staining respectively. Cells cultured in 
basal hMSC medium (A, B) or chondrogenic medium without TGF-β1 (C) served as 
negative controls (Ctrl). Chondrogenic images are representative of biological 
triplicates. Scale bar: 100 μm. (D) Quantification of Alcian blue stain showing the 
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2.3.6. Effects of heparin on TGF-β1 signalling in hMSCs 
 Having isolated primary hMSCs, we next examined if the interaction between 
heparin and TGF-β1 could influence the cellular response to TGF-β1 signalling, 
which was measured by way of the downstream phosphorylation of SMAD2 and 
SMAD3. Heparin has been shown to potentiate the effects of TGF-β1 in primary rat 
and bovine smooth muscle cells (SMCs) and the CCL64 mink lung epithelial cell line, 
but not in primary human saphenous vein (SMCs) [41, 69]. We therefore postulated 
that should heparin potentiate TGF-β1 activity in hMSCs, the effects would only be 
seen as the pSMAD2 and pSMAD3 signals from TGF-β1 alone started to subside. 
Thus the time points chosen for our initial TGF-β1 dosing experiment were 6, 12, 24 
and 48 h.  
Passage 5 hMSCs were treated with a range of TGF-1 doses and total cell 
lysate collected at 6, 12, 24 and 48 h post treatment. Lysate samples were then 
resolved on 4-12% (w/v gradient) SDS-PAGE gels, transferred onto a nitrocellulose 
membrane and probed for phospho-SMAD2 (pSMAD2) (138D4, Cell Signaling 
Technology), phospho-SMAD3 (pSMAD3) (C25A9, Cell Signaling Technology), 
total SMAD2/3 (Cell Signaling Technology) and actin (Clone C4, Merck Millipore) 
by Western blotting (Fig. 2.11). Our results showed that without TGF-β1 (0 ng/mL), 
there was a low background level of pSMAD2 and pSMAD3 signalling. With 1 
ng/mL, the pSMAD2 signal was quite intense at 6 h post treatment, and started to 
subside from 12 h onwards. The pSMAD3 signal mirrored that of the pSMAD2 
signal, albeit at a lower intensity. With both 5 ng/mL and 10 ng/mL TGF-β1, the 
pSMAD2 signal was seen to remain saturated across all the time points tested, but the 
pSMAD3 signal returned to background levels by 24 h. The 6 h time point was thus 
chosen for all subsequent experiments. 
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FIGURE 2.11. Optimisation of TGF-1 dosing in hMSCS. Passage 5 cells were 
treated with various doses of TGF-1 and lysed at the indicated time points. 
Phosphorylated SMAD2 (pSMAD2), phosphorylated SMAD3 (pSMAD3), total 
SMAD2/3 (SMAD2/3) and actin levels were detected by Western blotting. 
 
 Our next goal was to determine the dose of heparin to use for our experiments. 
As McCaffrey et al. [41] have previously reported the effective TGF-1-potentiating 
dose of heparin to be between 1-100 μg/mL, we chose to use doses within this range. 
Cells that were treated with 1 ng/mL of TGF-1 pre-incubated with 10 g/mL of 
heparin maintained a stronger pSMAD2 and pSMAD3 signal compared to cells 
treated with the same dose of TGF-1 alone (Fig. 2.12). A higher dose of heparin (40 
g/mL) was unable to elicit the same effect with 1 ng/mL of TGF-1. When pre-
incubated with 5 ng/mL of TGF-1, neither dose of heparin was able enhance the 
pSMAD signal beyond that obtained from the growth factor alone. Taken together, 
our results suggest that heparin enhances the pSMAD signals produced by TGF-1. 
 
 
                                                                 73 
CONFIDENTIAL 
 
FIGURE 2.12. Effect of heparin on TGF-β1 signalling in hMSCs. Passage 5 cells 
were treated the indicated doses of TGF-1 that had been pre-incubated with either 10 
or 40 g/ml of heparin and lysed after 6 h. (A) Phosphorylated SMAD2 (pSMAD2), 
phosphorylated SMAD3 (pSMAD3), total SMAD2/3 (SMAD2/3) and actin levels 
were detected by Western blotting. Densitometry of (B) pSMAD2 and (C) pSMAD3 
levels relative to 1 ng/mL TGF-β1 without heparin (0 μg/mL). Error bars represent 
standard deviation, n = 3. 
 
We next sought to examine the influence that cell surface HS might have on 
TGF-1-driven SMAD signalling. To do so, passage 5 cells were treated with 
heparinase I, II and III (1.2 mIU/mL each) for 24 h in hMSC culture medium, before 
being treated with TGF-1 with or without heparin in serum-free medium. The 6 h 
time point used for Western blotting necessitated the use of serum-free media after 
heparinase treatment, in order to avoid the effects that the growth factors in the serum 
would have on background levels of SMAD2 and 3. Immunofluorescence staining of 
cell surface HS with the anti-HS 10E4 antibody showed that after 24 h treatment, 
nearly all the cell surface HS had been removed (Fig. 2.13A, B). However, the 
removal of cell surface HS did not appear to affect the pSMAD signals produced 
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when the cells were treated with TGF-1 (Fig. 2.13C-H). Our results suggest that the 
role played by heparin in potentiating TGF-1 signalling is different from the role it 
plays in FGF-2 signalling [128]. 
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FIGURE 2.13. Heparinase treatment does not affect TGF-β1 signalling in hMSCs. 
Cell surface HS expression after 24 h (A) without (- Heparinase) or (B) with 
heparinase (+Heparinase) treatment. HS was stained with 10E4 antibody (green, 
FITC-conjugate secondary antibody) and nuclei were stained with Hoechst 33342 
(blue). Treatment of passage 5 cells (C) without (- Heparinase) or (D) with heparinase 
(+ Heparinase), for 24 h prior to treatment with the indicated doses of TGF-1 and/or 
heparin (Hep), had no discernible effect on the ability of heparin to potentiate the 
pSMAD2 (E, F) and pSMAD3 (G, H) signals, based on densitometry, in hMSCs at 6 
h post treatment. Scale bar: 50 μm 
 
2.3.7. Effects of heparin length and sulphation on TGF-β1 signalling in hMSCs 
 Having determined that heparin did indeed influence TGF-1 signalling, we 
next sought to determine the effects that heparin size and sulphation would have. 
Western blot analysis of pSMAD2 and pSMAD3 levels in cells treated with the 
varying fragments lengths of heparin (dp14-24, 10 g/mL of each fragment) and 
TGF-β1 (1 ng/mL) at 6 h post treatment yielded surprising results. Instead of the 
expected length-dependent increase in the potentiating activity of the various heparin 
fragments, the cells that had been treated with TGF-β1 and heparin fragments 
between dp18 and dp22 displayed greater pSMAD levels relative to those treated with 
unfractionated heparin (Hep) and TGF-β1, with signals peaking with the dp22-TGF-
β1 combination (Fig. 2.14). This suggests that the length of the heparin chain exerts 
considerable influence over its ability to potentiate the TGF-β1 signal and that the 
potency of the effect may be dependent on saccharide size. 
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FIGURE 2.14. Effect of heparin length on TGF-β1 signalling in hMSCs. Cells were 
treated with TGF-β1 (1 ng/ml), pre-incubated with 10 μg/ml of the various heparin 
fragments (dp14-24) or unfractionated heparin (Hep) for 10 min at room temperature, 
and lysed at 6 h. Phosphorylated SMAD2 (pSMAD2) and SMAD3 (pSMAD3), total 
SMAD2/3 and actin levels were determined by (A) Western blotting. Densitometry of 
(B) pSMAD2 and (C) pSMAD3 levels. Error bars represent standard deviation, n = 3. 
 
The results from cell studies with the chemically modified heparins were 
similarly unexpected. Instead of the reduction we expected to see in the pSMAD 
levels from cells treated with 2-O-desulphated heparin for 6 h, relative to fully 
sulphated heparin (Hep), we observed an increase to levels beyond those seen in 
heparin-treated cells (Fig. 2.15, Sup. Fig. A5), suggesting that 2-O-desulphated 
heparin potentiated TGF-β1 signalling even more than fully sulphated heparin. 
Similarly, the removal of 6-O-sulphation also brought about a stabilisation of pSMAD 
levels relative to those seen for the heparin-treated cells. The loss of N-sulphation 
however, did not lead to an increase in pSMAD levels relative to those from heparin-
treated cells.  
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FIGURE 2.15. Effect of heparin sulphation on TGF-β1 signalling in hMSCs. Cells 
were treated with TGF-β1 (1 ng/ml), pre-incubated with 10 μg/ml of the various 
selectively desulphated (2-O-de, 6-O-de or N-de) or fully sulphated heparin (Hep) for 
10 min at room temperature, and lysed after 6 h. Phosphorylated SMAD2 (pSMAD2) 
and SMAD3 (pSMAD3), total SMAD2/3 and actin levels were determined by (A) 
Western blotting. Densitometry of (B) pSMAD2 and (C) pSMAD3 levels.  
 
Collectively, the data indicate that the loss of 2-O-sulfation from heparin, and 
to a lesser degree 6-O-sulfation, actually improves the ability of heparin to potentiate 
the TGF-β1 signal. 
 
2.4. Discussion 
 The development of HS-based therapies has the potential to open up an 
entirely new range of treatment modalities for tissue repair and wound healing. As 
part of the first steps needed to unlock this vast therapeutic potential of HS, we sought 
to examine and appreciate the interaction between TGF-β1 and heparin and its effect 
on cells. Thus in this chapter, we have identified a novel lysine residue (K291) in 
TGF-β1 that is involved in heparin binding, and validated the predicted heparin-
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binding sites on the protein homodimer. The structural requirements needed for 
heparin to effectively bind to TGF-β1 have also been elucidated. Our data indicate 
that a minimum of 18-20 saccharides are needed and that a hierarchy exists for the 
specific sulphate groups (2-O < 6-O < N-sulphates) on the heparin chain when 
interacting with TGF-β1. The in vitro data suggests that heparin potentiates TGF-β1 
signalling by increasing the half-life of the TGF-β1-driven pSMAD signal rather than 
its maximum intensity. Also, the removal of cell surface HS does not appear to alter 
the cellular response to heparin-bound TGF-β1. Finally, we show that the relationship 
between binding and activity is a complex one. Our data show that dp18 and dp22 
fragments of heparin were better able to potentiate the TGF-β1-driven pSMAD signal 
relative to unfractionated heparin, and that the loss of specific sulphate groups (i.e. 2-
O-sulphates), while reducing binding to TGF-β1, actually serves to improve its 
bioactivity. 
 Previous approaches to the identification of heparin-binding domains in 
proteins relied heavily on the identification of linear consensus sequences [66, 112, 
151]. While yielding relatively accurate predictions, such an approach fails to account 
for the presence of binding sites that are only apparent in the folded protein [158]. 
Vivès et al. [179] have developed a technique for the direct mapping of heparin-
binding residues that utilises N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (EDC)/NHS chemistry to identify interacting amino acid residues via 
N-terminal sequencing. However, the method involves the covalent coupling of the 
protein of interest to activated carboxyl groups on the heparin chain. The problem is 
that the alteration of the heparin chain almost certainly in turn alters the interaction 
between it and the protein of interest.  
                                                                 79 
CONFIDENTIAL 
To overcome these limitations, Ori et al. [124] have developed a mass 
spectrometry based approach for the identification of heparin-binding sites in proteins 
that does not involve alterations to the interacting regions of both the polysaccharide 
and protein. Using this technique, we were able to validate both the previously 
predicted heparin-binding sites on TGF-β1 [66] and the currently proposed binding 
model [68] (Fig. 2.16A). In fact, our identification of the K291 residue improves the 
original model and provides a basis for the orientation of the heparin chain between 
the two TGF-β1 monomers (Fig. 2.16B). The location of the K291 residues on the 
protein homodimer may aid in guiding the heparin chain through the hydrophobic 
region that exists between the K304 residues (K26 on the Lyon et al. model) on either 
monomer. When coupled with our data on the size requirements for heparin and the 
report on heparin structures by Khan et al.[180], we can see how a dp20 or dp22 
would be able to bridge the distance between the opposing K304 residues. Site-
directed mutagenesis of this residue would allow us to more thoroughly test our 
hypothesis and will be pursued in further work. 
While it is widely accepted that heparin is able to bind to TGF-β1, reports on 
the effects of this interaction remain conflicting. Some groups have reported that 
heparin potentiates TGF-β1 activity by preventing its association with, and clearance 
by α2-macroglobulin (α2M) [41, 69], and that this effect is not seen when cells are 
cultured without serum [68]. Others have reported that heparin binding to TGF-β1 has 
either no effect on pSMAD levels [181], based on a single 30 min time point, or 
inhibits TGF-β-SMAD signalling [70, 71]. Given the pleiotropic effects of TGF-β1, it 
is possible that these observations are cell-type dependent. Our data suggests that 
heparin potentiates TGF-β1-driven pSMAD levels in hMSCs. Moreover, the removal 
of cell surface HS and serum did not alter the cellular response to heparin-bound 
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TGF-β1. This strongly suggests that the role played by heparin in potentiating TGF-
β1 activity is different from that played in FGF-2 and BMP-2 signalling [129, 151, 
154, 157, 161, 182]. Rather than aiding in the assembly of the TGF-β1 receptor 
signalling complex, as is the case for FGF-2 and BMP-2, heparin may be acting to 
stabilise and preserve active levels of TGF-β1 [63]. Our observation that in the 
absence of serum, and thus α2M, heparin was still able to prolong the effects of TGF-
β1 in hMSC cultures appears to support this hypothesis, and we will explore this in 
more detail later in this discussion. 
The results obtained from our bioassays of the heparin-TGFβ1 interaction 
proved to be very surprising. While it was found that a dp20 was sufficient to bind 
TGF-β1 at a level similar to that of heparin, our data showed that a dp22 was able to 
potentiate TGF-β1 activity better than heparin, suggesting that there is a degree of 
specificity in the structure of heparin required for these interactions. This would argue 
that the abundance of HS structures that TGF-β1 recognises in the ECM would be less 
than those recognised by FGF-2, which only requires a decasaccharide (dp10) [128, 
155], and therefore affect the subsequent transport of mature TGF-β1 in the ECM 
[130], enabling it to travel further away from its site of production. It is also 
interesting to note that unlike many growth factors, which recognise and bind shorter 
heparin chains [170], TGF-β1 requires a chain length similar to those seen in heparin-
chemokine interactions [183]. As TGF-β1 is also known to be a potent chemotactic 
factor [184], this may be an evolutionary mechanism for the differential regulation of 
chemokines and cytokines, where the former generally need to act at greater distances 
than the latter. 
The role of the various sulphate groups in heparin-TGF-β1 binding and 
bioactivity was equally surprising. The synthesis of HS in vivo begins with the 
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elongation of the nascent polysaccharide chain followed by the addition of N-sulphate 
groups. This is followed by the epimerisation of glucuronic acid (GlcA) to iduronic 
acid (IdoA) and the addition of 2-O-sulphate groups to the IdoA residues. Finally, 6-
O-sulphate groups are added to IdoA residues that may or may not already have a 2-
O-sulphate. Our data show that while the loss of either 2-O or 6-O sulphate groups on 
heparin reduces its binding to TGF-β1, they do not cause a corresponding reduction in 
bioactivity. In fact, the loss of 2-O-sulphates actually increased the TGF-β1-
potentiating ability of heparin. This would imply that TGF-β1-binding sites in HS are 
more likely to be found in the NA/NS regions where there is a lower density of 
sulphate groups. Our findings that the loss of N-sulphate groups abolishes both the 
binding and potentiating activity of heparin further substantiate this hypothesis. 
Collectively, the data supports our model for TGF-β1-heparin binding (Fig. 2.16B), as 
the reduced sulphate density would both endow the HS chain with a greater degree of 
flexibility, and reduce its exclusion radius and thus the steric hindrance that would be 
encountered when the chain navigates the hydrophobic space between the identified 
heparin-binding sites on either end of the TGF-β1 dimer. It should be noted that the 
N-desulphated heparin variant used in our experiments was not N-re-acetylated, so it 
is possible that the interactions observed with TGF-β1 may not be representative of 
the interaction between TGF-β1 and heparin/HS in vivo. Also, the use of doubly 
desulphated heparin variants would allow us to further investigate and improve our 
model-hypothesis [185]. 
TGF-β1 has been shown to play roles in fibrosis [71, 186], skin healing [98], 
cancer metastasis [17, 187] and chondrogenesis [12, 81, 99, 188, 189]. As such, its 
activity is very tightly regulated through its production in a latent form, known as 
latent TGF (LTGF), and the subsequent binding of LTGF to LTGF binding proteins 
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(LTBPs), which in turn are sequestered in the ECM. Activation of latent TGF-β1 
(LTGF) has been reported to be inhibited by heparin, through the binding of the 
heparin chain to both the mature TGF-β1 protein and the latency associated peptide 
(LAP) [63]. The crystal structure of porcine LTGF shows that the LAP wraps around 
the mature TGF-β homodimer like a pincer (PDB: 3RJR) [51] (Fig. 2.16C) and 
disrupts the structure of the heparin-binding domain (Fig. 2.16D). It is possible that a 
heparin/HS chain could bind LTGF and secure the mature TGF-β1 within the grasp of 
LAP, as suggested by Lee [63] (Fig. 2.16E), or that a heparin/HS chain could bind to 
mature TGF-β1 and prevent its association with LAP (Fig. 2.16D). Both theories are 
equally plausible and would explain the conflicting reports on the effect of heparin on 
TGF-β1 activity. We believe that the effects seen will be cell- or tissue-dependent as 
the function of both TGF-β1 and HS varies with tissue type [23, 107, 108, 190, 191]. 
For hMSCs, heparin appears to act in the latter role as our results indicate that active 
levels of TGF-β1 are maintained for longer periods, based on the increased duration 
of pSMAD signals. Even when treated with heparin-bound TGF-β1 for 6 h in serum 
free medium after 24 h of treatment with heparinase, hMSCs still exhibited the same 
extended duration of the pSMAD signal. It may be that heparin not only prevents the 
clearance of TGF-β1 by α2M, but also stabilises and lengthens the half-life of active 
TGF-β1 in solution. Current knowledge of the tight regulation of active TGF-β1, 
coupled with our findings on the interaction of TGF-β1 and heparin, and the 
supposition that this increased length requirement may influence the proteins transport 
in the matrix all lend support to this idea. Additionally, TGF-β1 has been shown to 
induce the expression of HS 6-O-endosulfatase (Sulf1) [181], which removes 6-O-
sulphates from HS and thereby negatively regulates TGF-β1 activity.  
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FIGURE 2.16. Proposed model for heparin-TGF-β1 binding. According to the model 
proposed by Lyon et al. [68] (A), the heparin/HS chain (red and yellow chain 
representing a dp26 fragment) interacts with TGF-β1 through the K304 (K26 on the 
Lyon et al. model) residue on either monomer (B). This model would involve the 
heparin/HS chain (red and yellow chain representing the alternating uronic acid and 
glucosamine residues) having to navigate the groove between the interfaces of the two 
protein monomers. The position of K291 would aid the sugar chain in the adoption of 
such a spatial orientation needed for binding to TGF-β1. Comparison of the predicted 
TGF-β1 structure with recently published heparin structures by Khan et al. [165, 180] 
also suggests that a dp22 heparin fragment would be sufficient to bridge the distance 
between the K304 residues on either monomer. (C) Ribbon diagram of LTGF-β1 
demonstrating how the latency associate peptide (LAP) (beige) wraps around the 
TGF-β1 homodimer (grey) (PDB: 3RJR [51]). Applying the same heparin-binding 
model from figure 2.16B to the LTGF-β1 structure, the K291 residues may aid in the 
orientation of the heparin/HS chain (red and yellow chain) to either interfere with the 
binding of LAP (beige) to mature TGF-β1 (D) or stabilise it [63] (E). Basic residues 
in LTGF-β1 are coloured light blue. 
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 The TGF-β superfamily consists of over 30 different proteins [192, 193] and 
thus far nearly a quarter have been reported to bind heparin/HS [194]. Like the FGF 
superfamily, members of the TGF-β superfamily share structural similarities. Xu et al. 
have recently reported on the diversification of heparin-binding sites within the FGF 
superfamily [158] and Rider has alluded to a similar case for the TGF-β superfamily 
[194]. We thus sought to explore this idea through the comparison of the TGF-β1 
heparin binding site/model with that of BMP-2, a well-studied heparin-binding family 
member [112]. Unlike TGF-β1, the heparin-binding domain in BMP-2 is located at 
the N-terminus of the protein [112, 148], and the BMP-2 homodimer contains a large 
number of acidic residues, instead of basic residues, at its extreme ends. This suggests 
that the model for heparin binding to BMP-2 will be different from that of TGF-β1, 
and that the minimum unit of heparin required for binding to BMP-2 will be shorter 
than that required for TGF-β1. Structural alignment of the TGF-β1 structure with that 
of BMP-2 (PDB: 3BMP) [195], shows that an arginine residue (R291) in the BMP-2 
heparin binding site aligns with the newly identified K291 of TGF-β1 (Fig. 2.17). It is 
possible that TGF-β1 may be able to bind heparin/HS (red and yellow chain 
representing a dp16 fragment) in a manner similar to that of BMP-2, through a 
secondary binding site, wherein the heparin chain spans the groove formed between 
the K291 residues on either monomer. Separately, there is evidence that the loss of 2-
O-sulphates also enhances the activity of BMP-2 in vivo [196]. It is thus possible that 
while heparin/HS binding sites may not be strongly conserved between members of 
the TGF-β superfamily, the structural characteristics that govern their binding to 
heparin/HS are. 
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FIGURE 2.17. Conservation of residues between TGF-β1 and BMP-2 – an alternate 
binding model for heparin. Structural alignment of the human BMP-2 monomer (top) 
(PDB: 3BMP [195]) with the TGF-β1 homodimer (bottom) (PDB: 1KLC [50]) shows 
that the R291 residue in the heparin binding domain of BMP-2 [164, 165, 197] aligns 
with the newly identified K291 residue in TGF-β1. It is thus possible that TGF-β1 
may be able to bind heparin/HS (red and yellow chain representing a dp16 fragment) 
in a manner similar to that of BMP-2, where the heparin chain spans the groove 
formed between the K291 residues on either monomer. Arginine (R) and lysine (K) 
residues are coloured blue. 
  
The work reported in this chapter underscores the need to better understand 
the structural factors influencing the interaction of heparin/HS with heparin-binding 
proteins. More importantly, it highlights the complex relationship between binding 
and activity in heparin/HS-protein interactions, and lays the foundation for further 
structure-function analyses of other growth factors. As the heparanome continues to 
grow, there will be a need to more accurately map heparin binding sites on the 3D 
structures of heparin-binding proteins [25, 198]. Such information will aid in our 
drive to understand sugar-coding and accelerate the development of HS-based 
therapeutics. 
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2.5. Limitations of this study 
While it was necessary to use heparin-coated beads during the ‘Protect and 
Label’ experiment to identify the heparin-binding residues in TGF-β1, the immense 
net negative charge on heparin may have led to an altered interaction with TGF-β1 
relative to HS, which is comparatively less charged and more heterogenous. Also, the 
use of NHS chemistry precluded the identification of heparin-binding arginines and 
other potential hydrogen bond donor/acceptor amino acid residues [112]. As such, we 
are still unable to paint a complete picture of heparin/HS-TGF-β1 interaction.  
As well as these considerations, the use of additional hMSC donors in the 
testing of the effects of heparin on the activity of TGF-β1 would have aided in further 
validating our findings. Here, pSMAD levels were used as a measure of the 
potentiating effect of heparin on TGF-β1, as it is the default signalling pathway for 
TGF-β1 [56]. However, TGF-β1 is also able to signal indirectly through the mitogen-
activated protein kinase (MAPK) pathway [199]. A more in-depth study of the precise 
mechanism of action of heparin in potentiating TGF-β1 is therefore warranted. 
 
2.6. Summary 
 This chapter has identified the heparin-binding residues in TGF-β1 and 
examined the effect that binding to heparin has on its activity. We have also 
determined the size and charge requirements for the interaction of heparin/HS with 
TGF-β1 and proposed an improved model for their interaction. Equipped with this 
data, we have developed a better understanding of the nuances of heparin/HS-TGF-β1 
interactions and now poised to develop an HS variant with an improved affinity for 
TGF-β1. In the development of this HS variant, we endeavour to mimic the activity of 
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heparin while removing its associated anti-coagulant effects and reducing its protein-
binding promiscuity. 
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CHAPTER 3.  ISOLATION AND CHARACTERISATION OF TGF-β1-




 Recent studies have demonstrated that heparin will bind to TGF-β1 and 
protect it from protease activity and circulatory clearance by α 2-macroglobulin, thus 
enhancing its signal [41, 69]. This has led to its use as either a TGF-β carrier or as a 
scaffold material in some cartilage repair studies [100, 200]. Some studies have even 
utilised heparin to control the release of growth factors during the chondrogenic 
induction of murine MSCs [8]. However, this sugar is unlikely to see widespread 
adoption as a therapeutic agent for tissue repair or growth factor modulation in its 
native state, not only because of the risk of uncontrolled bleeding through anti-
coagulation and initiation of thrombocytopenia [139], but because its cross-reactive 
hypersulphation means that is capable of promiscuously binding to over 300 different 
extracellular proteins, collectively known as the heparin interactome or heparanome 
[25, 201]. Conceptually, heparin is just as capable of binding the inhibitor of a growth 
factor, such as noggin or chordin [202-204], or a proteolytic activator [205] as the 
growth factor itself. Thus heparin does not possess sufficient specificity to be used for 
targeted growth factor modulation in an in vivo system, where growth factor 
production and localisation cannot easily be controlled. 
The use of HS, rather than heparin, could theoretically overcome these 
hurdles, as HS possesses a greatly reduced anticoagulant activity relative to  heparin 
[206]. However, HS does give rise to its own set of problems, including the hyper-
variability of raw preparations. There are, however, techniques that have been 
developed to surmount these difficulties [23, 148, 207]. First developed by McCaffrey 
et al. for the affinity purification of heparin sub-fractions [66], these techniques utilise 
                                                                 89 
CONFIDENTIAL 
heparin-binding peptides, derived from the protein of interest, in an affinity 
chromatography system to selectively isolate sub-fractions of either heparin or HS 
with increased affinity for the protein of interest. While it has been reported that HS 
composition varies between tissues and genders [107, 208], the sheer abundance of 
porcine mucosal HS, which is produced as a waste product from the manufacture of 
clinical-grade heparin, presents a distinct cost advantage over the use of HS from 
other tissue sources.  
In this chapter, we utilise one of these techniques to isolate a TGF-β1-binding 
population of HS from a starting pool of unfractionated porcine mucosal HS [107, 
208]. We then examine the composition of the isolated HS and determine if an altered 
composition produces functional consequences for bioactivity with TGF-β1. 
 




To determine the heparin-binding ability of the TGF-β1-derived peptide 
(sequence - RKDLGWKWIHEPKGYH-AHX-K(Biotin)), 0.5 mg of the peptide was 
reconstituted in 1 mL of phosphate buffered saline (PBS). The peptide was then 
adsorbed onto a nitrocellulose disc (6 mm diameter) by incubating the disc in 1 mL of 
the reconstituted peptide at room temperature for 1 h with constant shaking. Discs 
incubated in PBS alone served as negative controls. After adsorption, the discs were 
dried in a vacuum oven at 80°C and 674.5 mBar for 45 min, washed 3 times with 
PBS, and then incubated with 1 mL of 0.1 µCi/mL 
3
H-heparin for 16 h at room 
temperature with constant shaking. The discs were then washed 4 times with PBS and 
the amount of 
3
H-heparin bound measured with a scintillation counter. 
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 was carried out as previously described [148] using the 
TGF-β1 peptide sequence described above. Briefly, 3 mg of the peptide was coupled 
to a HiTrap
TM
 streptavidin HP column (GE Healthcare, Buckinghamshire, UK), 
which was then used for affinity chromatography with commercially available porcine 
mucosal HS (HS
PM
, Celsus Laboratories Inc, Ohio, USA). HS
PM 
was dissolved at 1 
mg/mL in low-salt buffer (20 mM phosphate, 150 mM NaCl, pH 7.2), loaded at a 
flow rate of 0.2 mL/min and the column washed in the same buffer until the baseline 
absorbance at 232 nm (A232) reached zero. Bound HS was eluted in a single step with 
high-salt buffer (20 mM Phosphate, 1.5 M NaCl, pH 7.2), peak fractions were 
monitored at A232, collected, and the column re-equilibrated with low-salt buffer. The 
eluted (HS16
+ve)
 and flow-through (HS16
-ve
) peaks were collected separately, freeze-
dried, desalted on a HiPrep
TM
 26/10 desalting column (GE Healthcare, 











 samples were pooled and exchanged in D2O three 
times (three passes of dissolution of the dried powder in D2O (0.5 to 1 mL) and freeze 
dried until fully lyophilised) and the dry weight determined. NMR analysis was 
carried out at 30°C in 5 mm tubes as D2O solutions and included tBuOH (0.2 mg/mL) 
as an internal standard.  The optimum concentration for comprehensive data-sets was 
~15 mg/mL (
1
H), albeit the HS preparations were approximately 3 mg/mL. Proton 
(500 MHz) NMR spectra were recorded on a three channel Bruker AvanceIII500.  
The probe was a Bruker two channel 5 mm broadband Nuclei Probe (31P-109Ag) 
equipped with actively shielded 50 G/cm Z-axis Pulsed Field Gradients. The NMR 
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spectra were phase corrected, as required and were referenced to tBuOH (
1H δ 1.24 
ppm; 
13C (methyl) δ 30.29 ppm).  Assignments for signals were based on those 
reported by Guerrini et al. [209]. 
3.2.4. Alcian blue/Silver stain of GAG in native PAGE  







 samples, 2 μg of each GAG was run on a 12% native PAGE gel that had 
been pre-run at 80 V for 30 min to remove residual ammonium persulfate and 
tetramethylethylenediamine (TEMED). Samples were prepared in a final volume of 
25 μL with 4x electrophoretic mobility shift assay (EMSA) buffer (40 mM Tris-HCl, 
pH 8.0, 40% (v/v) ultrapure glycerol, 0.4% (v/v) NP40 and 400 mM KCl) diluted to 
1x with Tris-Glycine buffer (25 mM Tris, 192 mM Glycine). A molecular weight 
ladder and BSA were used as molecular weight markers, while heparin was used as a 
positive control for the Alcian Blue staining. The gel was then stained with 0.5% 
(w/v) Alcian Blue in 2% (v/v) acetic acid for 45 min, destained in 2% (v/v) acetic acid 
for 15 min and washed in MilliQ water overnight to remove excess stain. 
Subsequently, the gel was silver stained to visualise the protein markers and enhance 
the contrast of the Alcian Blue-stained GAGs. 
3.2.5. HPLC-size exclusion chromatography-refractive index (HPLC-SEC-RI) of 
affinity isolated HS 
HPLC-SEC-RI chromatograms were obtained using a TSKgel G4000PWxl 
column (7.8 mm x 30 cm) and a TSKgel G3000PWxl column (7.8 mm x 30 cm) 
(TOSOH Corp., Tokyo, Japan) in series on a Waters 2690 Alliance system with a 
Waters 2410 refractive index monitor (range 64). The dn/dc for quantification from 
the RI was set at 0.129.  Samples were injected (50 µg) and eluted with 50 mM 
ammonium acetate with a flow rate of 0.5 mL/min, at room temperature. Data was 
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collected and analysed using DAWN Astra software (Version 4.73.04, Wyatt 
Technology Corp., California, USA).  Heparin oligosaccharide standards, obtained 
from Iduron and Dextra (Reading, UK), were also run using the same conditions. Run 
times for these columns were 100 min in both cases. All GAG samples were at a 
concentration of 1 mg/mL in water. 







 samples were solubilised in water and filtered 
(Minisart RC15, 0.2 µm, Sartorius Stedim, Goettingen, Germany) to remove 
particulate matter.  The filtered solution was passed through a 2000 MWCO 
membrane (Vivaspin 2, Hydrosart, Sartorius Stedim), by centrifugation, and the 
retentate was recovered from the filter and lyophilised.  The purified HS samples were 
digested to di- and oligosaccharides by the sequential addition of heparin lyase 
enzymes (heparinase I (EC 4.2.2.7), heparinase II (EC unassigned) and heparinase III 
(EC 4.2.2.8) (Ibex Technologies Inc., Quebec, Canada) based on the method of 
Brickman et al. [152].  Dry HS samples (1 mg) were solubilised in digestion buffer as 
described by Lebrun and Linhardt [210] (500 µl; 50 mM sodium phosphate buffer, pH 
7.0) with 5 mIU of heparinase I and incubated (37°C, 2 h) with gentle 
inversion.  While some would argue that calcium ions are needed for heparinase 
activity [211, 212], Lohse and Linhardt have reported that the use of such ions should 
be avoided because of the conflicting data on their effects [213]. Heparinase III (5 
mIU) was added and incubated for 1 h, followed by heparinase II (5 mIU) for 18 
h.  Finally, 5 mIU of each of heparinase I, II and III were added simultaneously and 
incubated for 24 h.  The digestions were terminated by heating (100°C, 5 min).  All 
three HS samples were digested in duplicate and analysed by HPLC with UV 
detection (232 nm). 
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 digests (2 mg/mL) were diluted with water to 
100 µg/mL and filtered (0.2 µm, hydrophilic PTFE).  The analyses were performed on 
an Agilent 1260 Infinity liquid chromatography system (Agilent Technologies, 
California, USA) with an Agilent 1260 multiple wavelength detector monitored at 232 
nm.  The HPLC separation conditions were based on Skidmore et al. [214].  HS-
derived disaccharides were separated on a ProPac PA1 column (Thermo Scientific, 4 
mm x 250 mm) with a guard column, at 40°C.  Eluent A was water at pH 3.5 
(adjusted with HCl) and eluent B was 2 M NaCl at pH 3.5 (adjusted with HCl).  The 
gradient program was as follows: 0-1 min 0% eluent B, 1-32 min 0-35% eluent B, 32-
47 min 35-65% eluent B, 47-57 min 100% eluent B, 57-60 min 0% eluent B, at a flow 
rate of 1 mL/min.  Disaccharides present in the HS digests were identified from their 
elution times by comparison with elution times of twelve heparin disaccharide 
standards (Iduron Limited, Manchester, UK) and quantified against heparin 
disaccharide standard calibration curves. 
3.2.8. Plasmin digestion 
In order to determine the ability of the various GAGs to protect TGF-β1 from 







 or alone in PBS at room temperature for 10 min. 
Plasmin digestion was carried out by adding 0.5 mU of plasmin to the TGF-β1 
samples and incubating them at 37°C for 1.5 h. Samples were subsequently run on a 
4-12% (w/v gradient) SDS-PAGE gel and visualised by silver staining. All samples 
were made up to a final volume of 10 μL in PBS. 
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3.2.9. Alkaline Phosphatase (ALP) assay 
 To determine the effect of HS16
+ve
 on BMP-2 activity, C2C12 mouse 
myoblasts were seeded in duplicate at 20,000 cells/cm
2
 in complete C2C12 medium 
(DMEM-LG, 10% (v/v) FCS, 100 U/mL penicillin and 100 μg/mL streptomycin) and 
allowed to attach for 24 h. The complete medium was then replaced with treatment 
medium (DMEM-LG, 5% (v/v) FCS, 100 U/mL penicillin and 100 μg/mL 
streptomycin) with or without 100 ng/mL BMP-2 and/or 5 μg/mL HS16+ve, HS3+ve or 
HS
PM
 and the cells incubated for 3 days. Total cell lysate was then collected in RIPA 
buffer containing a protease inhibitor cocktail (Calbiochem, Merck Millipore, MA, 
USA) and protein content determined using a BCA protein assay kit (Thermo Fisher 
Scientific). ALP activity was measured by incubating 5 μg of protein with p-
nitrophenyl phosphate (Sigma-Aldrich) for 1 h at 37°C and reading the change in 
absorbance at 405 nm. RIPA buffer alone and 1 μL (10,000 U/mL) of calf intestinal 
phosphatase (New England Biolabs Ltd, Ontario, Canada) were used as negative and 
positive controls respectively. Each sample was read in duplicate to give a total of 4 
readings per treatment group. 
 
3.3. Results 
3.3.1. Isolation of affinity selected TGF-β1-binding HS (HS16+ve) 
 In the previous chapter, we identified some key structural features and 
requirements for heparin-TGF-β1 interactions. Our next goal was to isolate a TGF-β1-
binding fraction of HS from the heterogeneous pool that constitutes commercially 
available HS
PM
 preparations. To do so, we first designed a biotinylated heparin-
binding peptide derived from the sequence of mature TGF-β1 (Fig. 3.1A) and tested 
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its ability to bind to 
3
H-heparin (Fig. 3.1B).  The TGF-β1 peptide was then used to 
isolate a putative TGF-β1-binding population of HS using our HS affinity isolation 
platform, as previously described by Murali et al. [148]. HS that did not bind to the 
column was termed HS16
-ve
, while TGF-β1 peptide-binding HS that eluted from the 
column with 1.5 M NaCl, as denoted by the increase in conductivity, was termed 
HS16
+ve
 (Fig. 3.2). The use of full-length, native TGF-β1 instead of a peptide would 
not have been feasible because of the prohibitively high costs involved with the 




FIGURE 3.1. Identification of heparin binding TGF-β1 peptide. (A) Sequence of 
mature TGF-β1 showing the location and sequence of the peptide used for affinity 
isolation of the TGF-1-binding HS fraction. (B) 3H-heparin-binding assay to 
determine the ability of the selected peptide to bind to heparin. PBS was used as a 
negative control. Error bars represent SD, n = 2. 
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FIGURE 3.2. Isolation of TGF-β1-binding HS variants from a crude mixture of 
commercially available porcine mucosal HS (HS
PM
) by affinity chromatography. The 
first peak represents flow through (i.e. non-binding HS) from the TGF-1 peptide 
column after HS
PM
 loading and was designated HS16
-ve
. The second peak that 
appeared as conductivity (red line) increased was HS16
+ve
, the sub-fraction of the 
HS
PM
 that was elutable from the column (i.e. TGF-1 peptide-binding HS). 
 
3.3.2. Characterisation of affinity isolated HS fractions 
 Having isolated a fraction of TGF-1 peptide-binding HS from HSPM, we next 
sought to determine if it was compositionally different from both the non-binding HS 
fraction (HS16
-ve
) and the original starting material (HS
PM
). Proton-nuclear magnetic 
resonance (
1







revealed subtle differences in their corresponding spectra that were difficult to assign 





 were very similar to each other while HS16
+ve
 was less so. The most notable 
difference in the spectra of the three HS samples was the slight decrease in signal 
intensity at ~5.4 ppm of HS16
+ve
 (arrow, Fig. 3.3), which was assigned to the 
glucosamine acetates methyl resonance, as previously reported by Guerrini et al. 
[209]. This decrease was indicative of a slightly higher level of N-sulphation in 
HS16
+ve
 compared to the other two fractions. 





H-NMR of affinity-isolated HS fractions. Arrow indicates the 
decrease in intensity at the glucosamine acetate methyl resonance (~5.4 ppm) for 
HS16
+ve
. Signal assignments were based on those reported by Guerrini et al. [209]. 
 
 HS chains are known to vary greatly in terms of chain length [101], which 
partially explains their ability to bind to such a plethora of proteins. In order to 
enhance the relative specificity of an HS preparation for a given protein, it is 
necessary to reduce this variation. It was therefore relevant to examine the size 
distribution of polysaccharide chains within the three HS samples. Resolution of the 
three samples and heparin by native PAGE showed that HS16
+ve
 was predominantly 




 (Fig. 3.4A). Heparin, 
which is comparatively more homogenous than HS, was used to give an appreciation 
of the high heterogeneity present in HS preparations. To validate these findings, size-
exclusion chromatography (HPLC-SEC-RI) was carried out. The chromatograms 
from SEC indicated that HS16
+ve
 consists of a poly-disperse subset of the HS
PM
 from 
approximately dp8 to >dp26 (Fig. 3.4B).  However, the HS16
+ve
 population is 
enriched in HS with longer chain lengths (>dp26), which corroborates our data from 
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native PAGE and our earlier findings on the length requirements for heparin to bind 
TGF-β1 (Chapter 2).   
 
 
FIGURE 3.4. Size characterisation of affinity-isolated HS fractions. (A) Native 
PAGE gel stained with Alcian Blue and silver stain showing the size distribution of 






 and heparin. Note the 
relative homogeneity of the HS16
+ve
 after the purification step. A BSA standard was 
used as a marker for 66 kDa. (B) HPLC-SEC-RI chromatogram of the various HS 
fractions. Heparin oligosaccharide standards were used to indicate the approximate 
elution volumes. 
 





 were similar, HS16
+ve
 was enriched for ΔUA-
GlcNS,6S and ΔUA,2S-GlcNS,6S while containing relatively less ΔUA-GlcNAc, 
ΔUA-GlcNS, ΔUA,2S-GlcNAc and ΔUA,2S-GlcNS (Fig. 3.5). It should be noted that 
the rare ΔUA,2S-GlcNAc,6S disaccharide could not be detected with this HPLC 
technique. 
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FIGURE 3.5. Compositional analysis of affinity-isolated HS fractions as determined 







. Error bars represent error intervals, which were determined 
using student’s t-distribution with confidence limits set at 95. UA – Uronic acid; 
UA,2S – 2-O-sulphated UA; GlcNAc – N-acetyl-glucosamine; GlcNAc,6S – 6-O-
sulphated GlcNAc; GlcNS – N-sulphated-glucosamine; GlcNS,6S – 6-O-sulphated-
GlcNS. 
 
Taken together, the data indicate that the pool of HS that makes up HS16
+ve
 is 




 with respect to both size distribution and 
composition. Additionally, the relative reduction in ΔUA,2S-GlcNAc and ΔUA,2S-
GlcNS seen in HS16
+ve
 corroborated the earlier observation that the loss of 2-O-
sulfate from heparin actually served to increase its bioactivity towards TGF-β1 
(Chapter 2, Fig 2.15). The increased relative proportion of ΔUA,2S-GlcNS,6S may 
have resulted from the peptide preferentially enriching for saccharides with N- and 6-
O-sulfation, regardless of the presence of 2-O-sulfation.  




 binds to and potentiates TGF-β1 signalling 
 Given the difference in composition of HS16
+ve





, we next set out to investigate if these differences resulted in any functional 
consequences. Examination of the ability of these HS fractions to bind to TGF-β1 in 
competition assays (as described in Section 2.2.1) indicated that HS16
+ve
 was able to 
bind to TGF-β1 with a much higher affinity than HS16-ve or HSPM (Fig. 3.6). This 
indicated that the HS isolated with the TGF-β1 peptide was also able to bind to the 
complete protein. In order to further verify this, it was important to assess the ability 
of the sugar to mask the basic residues on the protein (i.e. the heparin/HS binding 






 (all at 10 
μg) with TGF-β1 (100 ng) for 10 min at room temperature before subjecting the 
samples to a plasmin digest. Given that plasmin preferentially cleaves the carboxyl 
face of lysine and arginine residues, we reasoned that if a sugar were to bind with any 
degree of specificity to TGF-β1, it should endow the protein with a degree of 
protection from the plasmin. Silver staining of the plasmin digestion products 
revealed that HS16
+ve
 (TGF-β1 + HS16+ve) was indeed better able to protect TGF-β1 
from plasmin digestion than any of the other sugars tested, including heparin (TGF-β1 
+ Hep) (Fig. 3.7). 
In the hMSC in vitro system described in Chapter 2 (see sections 2.2.4 and 
2.2.6), HS16
+ve
 was able to potentiate TGF-β1 signalling, via pSMAD2 and 





were unable to elicit a comparable response, reinforcing the earlier finding that 
HS16
+ve
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FIGURE 3.6. Binding of affinity isolated HS fractions to TGF-β1. Representative 
SPR sensograms showing the changes in binding response of 200 nM of TGF-β1 
when pre-incubated with either 5 or 10 μg of (A) HSPM, (B) HS16+ve, (C) HS16-ve or 
(D) heparin (Hep) prior to injection. (E) Bar chart depicts the ability of the various 
GAGs to compete for TGF-β1 binding against the heparin-coated surface. For clarity, 
the binding response of TGF-1 without any GAG (i.e. 0 g) is only shown for 
heparin. Data were normalised to 200 nM TGF-β1 alone. Error bars represent 
standard deviation, n = 3. N.D. – Not detectable. 
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FIGURE 3.7. Plasmin digestion of TGF-β1 with/without affinity-isolated HS 
fractions. Silver stained gel showing the ability of each GAG to protect TGF-β1 from 







 or alone in PBS at room temperature for 10 min. Plasmin 
digestion was carried out by adding 0.5 mU of plasmin to the TGF-β1 samples and 
incubating them at 37°C for 1.5 h. Samples were run on a 4-12% (w/v gradient) 








 potentiates TGF-β1 signalling in hMSCs. Cells were treated 







 for 10 min at room temperature, and lysed at 6 h. 
Phosphorylated SMAD2 (pSMAD2) and SMAD3 (pSMAD3), total SMAD2/3 and 
actin levels were determined by (A) Western blotting. Densitometry of (B) pSMAD2 
and (C) pSMAD3 levels. Error bars represent standard deviation, n = 3. 
 
As most TGF-β1 in vivo is found in an inactive latent form (LTGF-β1) [51, 
215], we next sought to explore the effects that HS16
+ve
 might have on it. Our data 
demonstrated again that HS16
+ve
 was able to significantly potentiate LTGF-β1-




 (Fig. 3.9). 
Collectively, the data shows that the HS16
+ve
 isolate is better able to bind to, and 
potentiate signalling driven by either TGF-β1 or the more physiologically abundant 




 potentiates LTGF-β1 signalling in hMSCs. Cells were treated 







 for 10 min at room temperature, and lysed after 6 h. 
Phosphorylated SMAD2 (pSMAD2) and SMAD3 (pSMAD3), total SMAD2/3 and 
actin levels were determined by (A) Western blotting. Densitometry of (B) pSMAD2 
and (C) pSMAD3 levels. Error bars represent standard deviation, n = 2. 
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3.3.4. Comparison of HS16
+ve
 and BMP-2-binding HS (HS3
+ve
) 
 Having shown that HS16
+ve
 enhances TGF-β1 signalling, it was of interest to 
determine if it might similarly enhance the activity of other members of the TGF-β 
superfamily. Our group has previously reported the affinity isolation of an HS 
fraction, HS3
+ve
, which enhances the activity of BMP-2 [148]. The structural 









 were found to contain 
similar amounts of ΔUA-GlcNAc, ΔUA-GlcNS and ΔUA,2S-GlcNS, while HS16+ve 
contained more ΔUA-GlcNAc,6S, ΔUA-GlcNS,6S and ΔUA,2S-GlcNS,6S and less 
ΔUA,2S-GlcNAc than HS3+ve. It must be noted that the composition of HS3+ve was 





determined by HPLC, so the ΔUA,2S-GlcNAc,6S disaccharide was not detected in 
the latter two samples. One could argue that the inability to detect this disaccharide 
would alter the compositional profile of the HS variants, but previous analyses of 
HS
PM
 using the CE method yielded composition profiles similar to the ones obtained 
with HPLC sans the ΔUA,2S-GlcNAc,6S disaccharide. It is therefore likely that the 
peak representing this disaccharide was erroneously assigned in the CE method. 
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 compositions. Bar chart 













 compositions were determined by 
HPLC, which was unable to detect the rare UA,2S-GlcNAc,6S disaccharide, while 
HS3
+ve
 composition was determined by capillary electrophoresis. Error bars represent 
error intervals, which were determined using student’s t-distribution with confidence 
limits set at 95. Data on HS3
+ve
 taken from [148] and used for comparison. 
 





functional consequences for their activity. Surprisingly, HS16
+ve
 was found to bind to 
BMP-2 better that HS3
+ve
 in SPR-based binding competition assays (Fig. 3.11). 
However, when investigated for its ability to potentiate the BMP-2 driven expression 
of alkaline phosphatase (ALP) in the mouse C2C12 myoblast cell line, the 
combination of HS16
+ve
 and BMP-2 was unable to effect the same level of ALP 
expression seen when HS3
+ve
 was used with BMP-2 (Fig. 3.12). 
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 binding to BMP-2. Representative 
SPR sensograms showing the changes in binding response of 25 nM of BMP-2 when 
pre-incubated with either 5 or 10 μg of (A) HSPM, (B) HS3+ve, (C) HS16+ve or (D) 
heparin (Hep) prior to injection. (E) Bar chart depicts the ability of the various GAGs 
to compete for BMP-2 binding against the heparin-coated surface. For clarity, the 
binding response of BMP-2 without any GAG (i.e. 0 g) is only shown for heparin. 
Data were normalised to 25 nM BMP-2 alone. Error bars represent standard deviation, 
n = 3. 
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FIGURE 3.12. BMP-2 potentiating ability of HS16
+ve







 to potentiate BMP-2-driven expression of alkaline 
phosphatase (ALP) in C2C12 cells. Error bars represent SD, n = 4. * P < 0.05, ** P < 
0.01, ** P < 0.001. 
 
 Collectively, the data show that HS that is affinity purified using a TGF-β1 
peptide is compositionally different from the original HS preparation, will bind to the 
full length protein and potentiate its activity both in its active and latent forms. Also, 
the HS purified with the TGF-β1 peptide is different from that purified with a BMP-2 
peptide and this difference is sufficient to alter or tune its activity towards TGF-β1 





 HS is known to bind to and influence over 300 proteins and plays a number of 
important roles in vivo [25, 47, 198], all of which serve to give it therapeutic 
possibility. However, a major hindrance for the capitalisation of its full therapeutic 
potential lies in its immense heterogeneity [101, 114]. In this chapter we have 
presented a technique for overcoming this hurdle. A peptide containing the heparin 
binding site of TGF-β1 was used to isolate a TGF-β1-binding fraction of HS from 
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porcine mucosal HS (HS
PM
) by affinity purification. The isolated TGF-β1-peptide 
binding HS, termed HS16
+ve
, was found to be compositionally different from the non-
binding HS fraction, termed HS16
-ve
, and the original HS
PM
 starting material. This 
variance in composition enhanced the ability of HS16
+ve
 to bind to, and modulate the 
activity of TGF-β1 relative to HS16-ve and HSPM. Surprisingly, HS16+ve was also able 
to modulate the activity of LTGF, the inactive, storage form of TGF-β1. When 
compared with HS3
+ve
, an HS variant developed to enhance BMP-2 activity [148], 
HS16
+ve
 was found to possess slight compositional differences, which altered its 





 A major premise of this technique is that a peptide derived from a given 
protein will be able to affinity purify an HS fraction that will bind to the protein. In 
this work, the peptide used was 16 amino acids in length, while full length mature 
TGF-β1 is 112 amino acids in length (Fig. 3.13). Peptides in solution are known to 
adopt conformations different from those assumed when part of a full protein, and 
structure predictions of the TGF-β1 peptide used for HS16+ve isolation, using PEP-
FOLD [216-218],  do not match its native structure in TGF-β1 (Sup. Fig. A4). This 
raises the question of the mechanism that drives our peptide-based affinity 
purification, as it is hard to conceive that a single stretch of peptide will be able to 
recreate the spatial organisation of the TGF-β1 heparin-binding domain. One could 
argue that the interaction between the peptide and HS is primarily driven by ionic 
interactions, which is almost certainly true for peptide-heparin interactions 
(unpublished data from our group), but it does not appear to be the case here as the 
use of a peptide from a different protein (BMP-2) alters the profile of the isolated HS 
fractions. Also, it does not explain how groups have been able to isolate heparin [66] 
and HS [148, 149] of varying characteristics using peptides. 
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FIGURE 3.13. Peptide used for isolation of HS16
+ve
. (A) Structure of TGF-β1 (PDB: 
1KLC [50]) with identified heparin binding residues, as reported in Chapter 2. (B) 
Ribbon diagram of (A) with the peptide coloured orange. Inset shows the peptide with 
the Arg and Lys residues coloured blue. 
 
 The extensively investigated consensus sequence of basic residues involved in 
heparin-binding is proposed to adopt one of two motifs of basic residues: -X-B-B-B-
X-X-B-X-X- or -X-B-B-X-B-X-X- (where X is any neutral or acidic amino acid and 
B is a basic residue) [67]. A third motif has been proposed to exist in TGF-β1: -X-B-
X-X-B-X-X-B-X-X-B-X- [66]. Intriguingly, Pace and Scholtz [219] have reported 
that basic residues have a high propensity to form α-helices in solution. Given the 
organisation of basic residues in these proposed motifs and that of the α-helix (3.6 
amino acid residues per turn), it would not be surprising to find that these motifs 
adopt a helical structure in solution with their basic residues arrayed along the same 
plane. If true, such organisation might confer some degree of selectivity to the 
peptides. 
 Sizing and compositional analysis of HS16
+ve
 showed that it was enriched for 
longer polysaccharide chains, less heterogeneous, in terms of chain size distribution, 
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. This nicely corroborated our findings from our study of heparin-TGF-β1 
interactions in Chapter 2, where we reported the need for heparin chains to be at least 
equivalent to a dp22 and possess 6-O- and N-sulphate groups in order to effectively 
bind to and modulate TGF-β1 activity. Enrichment for longer chains of HS can be 
explained by the need for at least 22 saccharide units to bridge the two heparin/HS 
binding sites on the TGF-β1 homodimer. Such chains would also have to satisfy the 
sulphate distribution criteria to effectively interact with TGF-β1, which would further 
narrow the range of HS chains selected by our purification. The striking similarity 
between the composition of HS16
+ve
 and the heparin requirements previously 
determined for TGF-β1-binding underscores the importance of structure-function 
studies for developing knowledge about heparin/HS-protein interactions. It also 
emphasises the continued relevance of using heparin as an HS analogue. 
 Given the composition of HS16
+ve
, it was not surprising that it was able to 
potentiate TGF-β1-driven SMAD signalling to a similar degree as heparin. What was 
unexpected was its effect on LTGF-β1 was more pronounced than that of heparin with 
LTGF-β1. As LTGF-β1 is the predominant form of TGF-β1 in vivo, this raises 
interesting questions about the synthesis of, and physiological role played by HS in 
TGF-β1 signalling. The latency-associated peptide (LAP) portion of LTGF has a 
structure considered to be stable, although two regions of the molecule can be 
unfolded [51] in such a way that it traps TGF-β1 in the LTGF-β1 complex. When the 
conformations of these regions are mechanically forced fully open, active TGF-β1 is 
released from the LAP [54]. This simultaneous unfolding of both domains, an all-or-
nothing snap mechanism necessary for full TGF-β1 release, is possible only when 
LAP is bound to LTGF-binding protein-1 (LTBP-1). It is interesting to note that both 
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LAP and LTBP-1 have been reported to interact with heparin [63-65]. Whether and 
how HS is involved in either the generation or release of this mechanical force is a 
pertinent question, though the evidence suggests that the HS synthesised in vivo may 
be tuned to activate LTGF-β1. 
 Comparison of the composition of HS16
+ve
 with that of HS3
+ve
 revealed only 
slight differences in their compositions. However, this reveals nothing about the 
actual and all-important sequence of these disaccharides. The differences observed in 
the ability of either HS variant to bind to and modulate BMP-2 activity is probably a 
result of a combination of the differences in composition and consequently the 
disaccharide sequences embodied in the HS chains. Modelling of the BMP-2-heparin 
interaction [112] suggests that the association varies significantly from that of heparin 
with TGF-β1, which would explain the differences in the compositions of HS16+ve 
and HS3
+ve
, and hints at the diversification of heparin/HS binding sites within the 
TGF-β superfamily [194]. The modest increase observed in the ability of HS16+ve to 
potentiate BMP-2 driven ALP expression relative to HS
PM
 might be attributable to 
either the enrichment of sulphated HS chains in HS16
+ve
, making it more similar to 
heparin than HS
PM






 This raises the important question of whether enrichment for the sulphated 
species of HS alone, rendering it more heparin-like, is sufficient to enhance its 
bioactivity with a host of proteins. Together with the reduction in heterogeneity that 
results from the enrichment, this would make a compelling argument for the effects 
we observe. Also, the reduced anticoagulant properties of HS compared to heparin 
[101, 139, 206, 220] further suggests that the use of highly sulphated HS alone would 
be significantly better as a therapeutic than heparin, which is currently being 
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employed in the development of a range of tissue engineering therapies [3, 6, 7, 70, 
71, 100, 138, 221-223]. However, this argument does not explain the distinctively 
different effects seen in the range of HS variants developed by our group [148, 149] 
or the varying needs for specific sulphation sites in growth factor signalling [107, 152, 
153, 156, 170, 224]. 
 While HS does not appear to be encoded with the same absolute sequence-
specificity seen in nucleic acids and proteins, our results provide compelling evidence 
for the current HS ‘sugar code’ hypothesis [105, 130, 153, 156] and reinforce the idea 
of a non-linear relationship between binding strength and bioactivity [225]. One of the 
major questions that remain to be answered is the level of stringency required for a 
given HS chain to interact with a given protein. It is hoped that the development of 
improved computational tools to decode the organisation of GAGs will aid in this 
endeavour [126]. Additionally, several groups have reported tissue/disease-specific 
differences in HS composition [107, 183, 190, 226, 227], so the current assumption 
we make about porcine mucosal HS – that it contains a sufficient spectrum of HS 
species to bind to the range of clinically relevant growth factors we are investigating - 
may need to be reassessed. Nonetheless, the HS purification technique described here 
remains the best option currently available to surmount the challenges inherent with 
the use of HS in the development of therapeutics for tissue repair.  
 
3.5. Limitations of this study 
As HS16
+ve
 was isolated using a peptide derived from TGF-β1, it would have 
been optimal to include a scrambled, charge-matched peptide as a control ligand. This 
would have ensured that the differences in our HS variants were due to the peptide 
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sequence rather than net charge. Also, had resources allowed, HS16
+ve
 could have 
been screened against a greater range of growth factors, including LTGF-β1, to 
determine its ability to bind to them. Such a screen would have further enhanced our 
understanding of the properties of HS16
+ve
 and enabled the better prediction of its 
effects both in vitro and in vivo. Finally, the dearth of techniques for HS sequencing 
continues to confine our analysis of HS16
+ve
 to just its average size and disaccharide 
composition, with little recourse to determining its linear disaccharide sequence. 
 
3.6 Summary 
 This chapter reports the isolation of a TGF-β1-binding fraction of HS, termed 
HS16
+ve
, from a starting pool of porcine mucosal HS using a patented HPLC-based 
affinity purification approach. The isolated HS was found to have an altered 
composition, which enhanced its bioactivity with TGF-β1 relative to the non-binding 
and original material. Additionally, HS16
+ve
 was found to differ in its ability to 
modulate BMP-2 activity compared to a BMP-2-binding HS preparation known as 
HS3
+ve
. Collectively, the data suggests that the use of a TGF-β1-derived peptide is 
sufficient to isolate HS species that will preferentially bind to the full TGF-β1 protein 
and modulate its bioactivity. Our next goal will be to evaluate the ability of HS16
+ve
 
to influence the chondrogenic differentiation of MSCs in vitro and in a clinically 
relevant animal model for cartilage injury.  
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CHAPTER 4. EFFECTS OF HS16+ve ON CHONDROGENIC 
DIFFERENTIATION OF MSCs IN VITRO AND IN VIVO 
4.1. Introduction 
 Articular cartilage is a tissue found at the ends of long bones that serves as 
both a shock absorber and lubricant in our joints. As a consequence of its avascular 
nature, injuries sustained by articular cartilage often fail to heal. Current research into 
the development of cartilage repair strategies has focused on stimulating the response 
from either endogenous or transplanted cells, through the use of activated biomaterials 
or provision of inductive cues to the cells [145, 228-234]. TGF-β1 has emerged as a 
key player for the induction of cartilage repair because of its ability to stimulate the 
chondrogenic differentiation of MSCs [14, 235, 236], and drive the expression of 
cartilage ECM molecules [84, 89, 99, 237, 238]. As such, most studies to date have 
employed the use of exogenous TGF-β1, either alone or in combination with other 
growth factors, to drive hMSC chondrogenic differentiation [87, 100, 144, 239]. 
While appearing successful initially, such approaches face significant barriers 
in their translation into the clinic, as supraphysiological doses of TGF-β1 are often 
employed, and even 20 ng doses have been shown to produce undesirable outcomes, 
such as synovial inflammation [85, 91]. Apart from the problem of non-physiological 
doses, there is also the need to localise the growth factor to the site of treatment to 
prevent it from triggering systemic side effects, such as fibrosis and oncogenesis [17, 
86, 187]. Additionally, sensitivity to TGF-β1 decreases with age [90], so adequate 
TGF-β1 dosing presents even more risk for aged patients. In response to these 
challenges, new strategies are being considered that reduce, or completely remove the 
need for exogenous growth factors; better localise and control the delivery of the 
growth factor at the site of treatment; and boost either cellular sensitivity to the 
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growth factor or the factor’s signalling efficiency. Some groups have already been 
able to surmount the first 2 hurdles through the use of self-assembling peptide 
amphiphiles [18, 19] and have demonstrated that endogenous levels of TGF-β1 are 
sufficient to drive local MSC differentiation [146]. However, synthetic peptide 
amphiphiles pose significant immunogenic risk [43], and fail to address the need to 
enhance signalling activity within cells. 
Having previously described the development of HS16
+ve
, and its ability to 
potentiate the TGF-β1-driven SMAD response in MSC monolayer cultures, we 
hypothesised that it could be used to improve cartilage healing by sequestering 
endogenous TGF-β1. It is hypothesised that the use of HS16+ve will not produce the 
same side effects associated with the use of increasing TGF-β1 concentrations, as the 
sugar is only active in the presence of TGF-β1. In the absence of the protein, HS16+ve, 
even at high doses, is unlikely to affect cell signalling or produce systemic side effects 
(unpublished data from the lab) as it does not stimulate an increase in growth factor 
concentrations. We thus sought to examine its effects on (1) the chondrogenic 
differentiation of hMSCs in vitro; and (2) the cartilage-healing response in a rabbit 
model. 
 This chapter describes the use of a modified micromass pellet culture system 
for the examination of the in vitro effects of HS16
+ve
 on the chondrogenic 
differentiation of hMSCS. It then moves on to examine the effects of the previously 
described HS variants, when used in conjunction with the current clinical “standard of 
care”, within a full depth, osteochondral defect of the trochlea groove in a rabbit 
model for cartilage repair.  
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4.2. Materials and methods 
4.2.1. Reverse transcription and quantitative PCR (qPCR) 
Total RNA was isolated from chondrogenic micromass pellets using TRIZOL 
reagent (Life Technologies, CA, USA) according to the manufacturer’s protocol. 
Reverse transcription was carried out on 1 μg of total RNA using the SuperScript® 
VILO
TM
 cDNA Synthesis Kit (Life Technologies) following the manufacturer’s 
instructions, with the incubation at 42°C being carried out for 2 h instead of 1 h. Each 
qPCR contained 40 ng cDNA, 1 μL TaqMan® primer-probe mix per gene, and 10 μL 
Taqman® Fast Universal PCR Master Mix (Life Technologies) in a final volume of 
20 μL. Thermal cycling conditions were 95°C for 20 s, followed by 45 cycles of 95°C 
for 1 s and 60°C for 20 s. Each qPCR was run in duplicate and gene expression was 
normalised to HPRT1 expression to obtain the ΔCt value. The average value of 
biological triplicates was taken. Chondrogenic micromass pellets cultured in media 
without GAG or TGF-β1 were used as controls (ΔΔCt). Relative expression levels for 
each primer set were expressed as fold changes by the 2
-ΔΔCt
 method [240]. The 
following TaqMan® primer-probe assays (Life technologies) were used:  
TABLE 4.1. List of primer-probe sets used in this study. All sets were designed by 
Life Technologies. 
Gene Abbreviation Assay ID 
Aggrecan ACAN Hs00153936_m1 
Cartilage oligomeric matrix protein COMP Hs00164359_m1 
Collagen, type II, alpha 1 COL2α1 Hs00264051_m1 
Collagen, type X, alpha 1 COL10α1 Hs00166657_m1 
Hypoxanthine phosphoribosyltransferase 1 HPRT1 Hs01003267_m1 
SRY (sex determining region Y)-box 9 SOX9 Hs00165814_m1 
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4.2.2. In vivo study design 
 Twenty-two skeletally mature, male New Zealand White rabbits (average age 
9 months and body weight 3.9 kg) were used for this study. All rabbits received 
bilateral osteochondral defects in the femoral trochlea groove and each defect was 





, and (4) Gel + HS16
-ve
. Every defect received 60 μL of a hyaluronic 
acid-based hydrogel (Gel) (AuxiGel
TM
, Termira AB, Stockholm, Sweden) [9] alone or 
with 10 μg of HSPM, HS16+ve or HS16-ve. Two rabbits died from gastric stasis post-
surgery and were not included in the analysis. 
4.2.3. Defect creation and gel injection 
 The research protocol used for this study was approved by the Institutional 
Animal Care and Use Committee, A*STAR Singapore, and followed all appropriate 
guidelines (IACUC #130833). All surgical procedures were carried out under general 
anaesthesia, consisting of a combination of ketamine (35 mg/kg) and xylazine (5 
mg/kg) injections and isoflurane via a face mask, and aseptic conditions. A medial 
para-patellar skin incision of 15-20 mm was made and the patella dislocated laterally. 
One full thickness, critically-sized osteochondral defect (4 mm diameter, 2 mm depth) 
was made in the centre of each femoral trochlea groove with complete debridement of 
the calcified cartilage. Subsequently, 3 microfractures (0.8 mm diameter, 2 mm depth) 
were made in each defect using an orthopaedic drill and direct pressure applied with 
surgical gauze to ensure all bleeding had stopped prior to the application of the 
designated treatment. Treatments were applied with a 200 μL pipette and allowed to 
set. All defects were observed to fill with blood while the gel carrier was setting. 
Once the gel carrier had set, the patella was repositioned and the joint flexed 15 times 
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to ensure the treatment remained in place before the incision was closed in layers, and 
rabbits allowed to weight-bear. The wound site was further sealed with Vetbond
TM
 
tissue adhesive (3M, MN, USA). Prophylactic antibiotics (Enrofloxacin, 10 mg/kg) 
and analgesics (Buprenorphin, 0.1 mg/kg) were administered subcutaneously for 5 
days post-surgery. At 12 weeks all rabbits were euthanized with pentobarbital (150 
mg/kg) after sedation. Distal femurs were harvested and imaged macroscopically 
before being processed for histological and immunohistochemistry (IHC) analysis. 
4.2.4. Gross pathologic observation of joints 
 Images of the joints were examined and scored by a blinded observer unaware 
of the treatment groups. Macroscopic scoring was based on the International Cartilage 
Repair Society (ICRS) Visual Assessment Scale (ICRS I scoring system) (Table A2) 
[241]. 
4.2.5. Histology analyses  
 Harvested distal femoral heads were fixed in 10% (v/v) neutral-buffered 
formalin (NBF) for 1 week under vacuum and decalcified in 5% (v/v) formic acid at 
room temperature for an average of 6-7 days. The samples were subsequently 
embedded in paraffin wax and sectioned (5 μm) across the middle of the defect. 
Sections were deparaffinised and stained with Masson’s trichrome, Alcian blue (pH 1, 
counterstained with neutral red) and Safranin-O. 
4.2.6. Immunohistochemistry (IHC) analyses 
 IHC staining was carried using either the Leica Bond
TM
-III or the Leica 
Bond
TM
-Max Autostainer (Leica Nussloch GmbH, Germany) and the Bond
TM
 Refine 
Detection Kit (Leica). Sections were deparaffinised with Bond
TM
 Dewax solution 
(Leica) and antigen retrieval carried out by incubating with Proteinase K (20 μg/mL) 
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(Sigma-Aldrich) for 15 min at room temperature. Endogenous peroxidase activity 
blocked by incubating with 3-4% (v/v) H2O2 for 15 min. Sections were then blocked 
in 10% (v/v) goat serum for 30 min before incubation with primary antibody 
(Collagen Type I (1:1000), Novus Biologicals, CO, USA and Collagen Type II 
(1:2000), Acris Antibodies, Inc., CA, USA) diluted in Bond
TM
 Primary Antibody 
Diluent (Leica) for 30 min at room temperature. Detection of staining was carried out 
as described in the Bond
TM
 Refine Detection Kit and nuclei were counterstained with 
haematoxylin for 5 min. All washes were carried out with 1x Bond
TM
 Wash Solution 
(Leica). 
4.2.7 Histological scoring 
 Examination and scoring of stained sections was carried out by a masked 
observer unaware of the treatment groups. Scoring was based on the O’Driscoll 
(Table A3) [242] and ICRS II (Table A4) [243] scoring systems, and tissue filling was 
determined by quantifying the percentage of each tissue type (i.e. bony tissue, fibrous 




4.3.1. Effects of HS16
+ve
 on chondrogenic differentiation of hMSCs in vitro 
 In order to assess the effects of HS16
+ve
 on the chondrogenic differentiation of 
hMSCs in vitro, it was first necessary to establish the effects of TGF-β1 alone. 
Chondrogenic differentiation was carried out using a modified micromass culture 
system as described in Chapter 2 (section 2.2.5). Wet weights of the resulting control 
(Ctrl) and TGF-β1-treated (10 ng/mL) (TGF-β1) micromass pellets were taken at days 
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3, 7, 14 and 21 (Fig. 4.1). While the weights of pellets in either treatment group 
decreased over time, the weight loss was less pronounced in TGF-β1-treated pellets 
than control pellets. 
 
FIGURE 4.1. Wet weight change in differentiating hMSCs. Graph showing the 
change in weights of chondrogenically differentiated pellets treated with (TGF-β1) or 
without TGF-β1 (Ctrl) over time. Errors bars represent SD, n = 3. *** P < 0.001 
compared to Ctrl. 
 
 Gene expression analysis of the micromass pellets at days 3 (SOX9 and 
COMP only), 7, 14 and 21 revealed that treatment with 10 ng/mL TGF-β1 (TGF-β1) 
consistently led to the increased expression of the chondrogenic markers SOX9 (Fig. 
4.2A), COMP (Fig. 4.2B) and aggrecan (Fig 4.2C) relative to untreated control pellets 
(Ctrl). Undifferentiated hMSCs were used as the day 0 control. Type II collagen 
transcripts were only detectable in TGF-β1-treated pellets and undifferentiated 
hMSCs (Fig. 4.2D). This appears to suggest that hMSCs express low levels of type II 
collagen transcripts when grown in monolayers, but this expression is lost when they 
are cultured as micromasses in chondrogenic medium without TGF-β1. Finally, TGF-
β1-treated pellets were found to express extremely high levels of type X collagen 
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transcripts, a marker of chondrocyte hypertrophy, relative to control pellets (Fig. 
4.2E). Such high expression levels suggest that the pellets are undergoing 
chondrogenic hypertrophy as a prelude to endochondral ossification [244]. 
Histological examination of the paraffin-embedded pellets at day 21 by Alcian blue 
staining, which stains GAGs blue, revealed that TGF-β1-treated pellets contained 
more GAGs then control pellets (Fig. 4.3). 
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FIGURE 4.2. Chondrogenic gene expression in differentiating hMSCs. Graphs 
showing (A) SOX9, (B) COMP, (C) Aggrecan, (D) Collagen type 2α1, and (E) 
Collagen type 10α1 mRNA expression levels over time in pellets treated with (TGF-
β1) or without (Ctrl) 10 ng/mL TGF-β1. Collagen type 2α1 mRNA was not detected 
in Ctrl pellets. Error bars represent SD, n = 3. * P < 0.05, ** P < 0.01, *** P < 0.001 
compared to Ctrl. 
 
 
FIGURE 4.3. Alcian blue staining of chondrogenically differentiated hMSCs. (A) 
Representative light micrograph images of hMSCs differentiated for 21 days with or 
without TGF-β1 in chondrogenic media. Sections were stained with Alcian blue, pH 
1, and counterstained with neutral red. Scale bar: 100 μm. (B) Quantification of 
Alcian blue staining showing the average mean grey value. Error bars represent SD, n 
= 3. * P < 0.05 
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 Having established the effects of TGF-β1 on the chondrogenic differentiation 
of hMSCs, we next sought to examine the effects that heparin has, before embarking 
on the investigation of the effects of HS16
+ve
. Prior work reported in Chapter 2.3.6 
showed that heparin was able to potentiate the TGF-β1-driven pSMAD signal in 
hMSCs at 6 h post treatment. Since medium was changed every third day during the 
chondrogenic differentiation process, we chose to use a day 3 time point to examine 
the effects of heparin on the expression of SOX9 and COMP, both early chondrogenic 
markers [82, 84, 245, 246]. We also reasoned that if heparin were to potentiate the 
effects of the TGF-β1, further increases in the response to the recommended dose of 
10 ng/mL might not be detectable, based on our results from Chapter 2.3.6. Therefore, 
a lower dose of TGF-β1 was used in parallel with the recommended dose. 
Our data show that 5 μg/mL of heparin did not significantly alter the level of 
SOX9 expression regardless of the amount of TGF-β1 used (Fig. 4.4A). Conversely, 
10 μg/mL of heparin on its own did not affect SOX9 expression, but when used in 
concert with 1 ng/mL of TGF-β1, it was able to increase the expression of SOX9. The 
same dose of heparin was unable to bring about any change in SOX9 expression when 
used with 10 ng/mL of TGF-β1, suggesting that the TGF-β1 signal was already 
saturated. In the case of COMP expression, both doses of heparin on their own were 
found to slightly reduce it (Fig. 4.4B). However, when used in combination with 1 
ng/mL TGF-β1, heparin was able to increase COMP expression levels in a dose-
dependent manner. The use of either dose of heparin with 10 ng/mL of TGF-β1 was 
unable to elicit a further increase in COMP expression. In fact, the higher dose of 
heparin actually reduced COMP expression levels. This again suggests that 10 ng/mL 
of TGF-β1 is a saturating dose for hMSCs undergoing chondrogenic differentiation. 
The reduction in COMP expression seen when 10 μg/mL of heparin was used with 10 
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ng/mL of TGF-β1 suggests the activation of a negative feedback mechanism in 
response to an excessive TGF-β1 signal.  
 
  
FIGURE 4.4. Effect of heparin on early chondrogenic gene expression. Bar charts 
showing (A) SOX9 and (B) COMP mRNA expression levels in hMSCs after 3 days 
of differentiation in chondrogenic media with the indicated treatments. Ctrl – control; 
5 Hep – 5 μg/mL heparin; 10 Hep – 10 μg/mL heparin; 1 TGF-β1 – 1 ng/mL TGF-β1; 
10 TGF-β1 – 10 ng/mL TGF-β1. Error bars represent SD, n = 3. * P <0.05, *** P < 
0.001 compared to Ctrl. 
#
 P <0.05, 
###
 P < 0.001 compared to 1 TGF-β1. 
 
 Based on the results obtained from the early gene expression assays and our 
results from Chapter 2.3.6, a dose of 10 μg/mL of GAG was selected to be used in 
conjunction with a 1 ng/mL dose of TGF-β1. Histological analysis of pellets cultured 
with either 1 ng/mL TGF-β1, 1 ng/mL TGF-β1 and 10 μg/mL heparin or 10 ng/mL 
TGF-β1 for 21 days showed that the higher dose of TGF-β1 lead to an increase in 
GAG production and deposition, based on Alcian blue staining (Fig. 4.5). The use of 
heparin with TGF-β1 lead to a slight increase in GAG deposition relative to 1 ng/mL 
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of TGF-β1 alone, but this increase was still less than that seen with 10 ng/mL of TGF-
β1.  
 
FIGURE 4.5. Effect of heparin on chondrogenic differentiation of hMSCs. (A) 
Representative light micrograph images of hMSCs differentiated for 21 days with the 
indicated treatments in chondrogenic media. Sections were stained with Alcian blue, 
pH 1, and counterstained with neutral red. Hep – Heparin. Scale bar: 100 μm. (B) 
Quantification of Alcian blue staining showing the average mean grey value. Error 
bars represent SD, n = 3. 
 
Next, hMSCs were differentiated for 21 days in the presence of 1 ng/mL TGF-





) or with 10 ng/mL TGF-β1 (10 TGF-β1) as a positive control. 
Analysis of SOX9 mRNA expression at 21 days showed that all the sugars used did 
                                                                 126 
CONFIDENTIAL 
not produce significant changes (Fig 4.6A). COMP expression increased ~2.5 fold, 
relative to 1 ng/mL TGF-β1 alone, when pellets were cultured with heparin or 
HS16
+ve
 (P < 0.05) in conjunction with 1 ng/mL TGF-β1 (Fig. 4.6B). Culture in 
medium supplemented with low (1 ng/mL) TGF-β1 and either HSPM or HS16-ve, or 
supplemented with high (10 ng/mL) TGF-β1 did not significantly alter COMP 
expression relative to low dose TGF-β1 alone. Aggrecan expression was similar with 
low and high doses of TGF-β1 and heparin and HS16+ve at day 21 (Fig. 4.6C). 




 reduced aggrecan transcript levels. High 
TGF-β1 induced a significant increase (P < 0.001) in type X collagen expression 
relative to low TGF-β1 (Fig. 4.6D). Treatment with GAGs did not significantly alter 
type X collagen expression relative to low TGF-β1. Type II collagen transcripts were 
only detected in pellets treated with high TGF-β1 and are thus not shown here. It 
should be noted that the high variance seen in all the samples treated with HS16
+ve
 (1 
TGF-β1+HS16-ve) stemmed from the presence of an outlier within the dataset.  
Histological examination of the pellets by Alcian blue staining at day 21 did 
not indicate significant differences between the pellets cultured with the various 
sugars, relative to low TGF-β1. High TGF-β did however induce a modest increase in 
GAG production compared to low TGF-β1 (Fig. 4.7). 
Collectively the data suggests that the sugar-induced potentiation of TGF-β1 
driven pSMAD signalling does not translate into any significant increase in early 
chondrogenic gene expression or chondrogenic pellet morphology. Moreover, the 
expression of chondrogenic genes after 21 days of differentiation is unable to present 
a clear picture of the state of differentiation that the cells are in. Whether this is an 
inherent shortcoming of the chondrogenic culture remains to be determined and will 
be discussed later in this chapter. Nonetheless, we decided to proceed with in vivo 
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work, based on an earlier report from our group that showed how in vitro performance 
was not altogether predictive of in vivo outcome [247]. 
  
FIGURE 4.6. Effect of isolated HS fractions on chondrogenic gene expression of 
hMSCs. Scatterplots showing (A) SOX9, (B) COMP, (C) Aggrecan and (D) Collagen 
type 10α1 mRNA expression levels in pellets cultured for 21 days in chondrogenic 
media with 1 or 10 ng/mL TGF-β1 (1 TGF-β1 and 10 TGF-β1, respectively) and 10 
μg/mL of the indicated GAG. Collagen type 2α1 mRNA was only detected in pellets 
treated with 10 ng/mL TGF-β1. Middle line represents mean, while error bars 
represent SD, n = 3. * P < 0.05, *** P < 0.001, compared to 1 TGF-β1. Note the 
outlier present in the 1 TGF-β1+HS16+ve dataset. 
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FIGURE 4.7. Effect of isolated HS fractions on chondrogenic differentiation of 
hMSCs. (A) Representative light micrograph images of hMSCs differentiated for 21 
days with 1 or 10 ng/mL TGF-β1 (1 TGF-β1 and 10 TGF-β1, respectively) and 10 
μg/mL of the indicated GAG in chondrogenic media. Sections were stained with 
Alcian blue, pH 1, and counterstained with neutral red. Hep – Heparin. Scale bar: 100 
μm. (B) Quantification of Alcian blue staining showing the average mean grey value. 
Error bars represent SD, n = 3. * P < 0.05. 
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4.3.2. Effects of HS16 on chondrogenic differentiation of MSCs in vivo 
 Skeletally mature adult New Zealand white rabbits were chosen for our in vivo 
trial based both on their extensive use in cartilage repair studies, and to avoid the 
spontaneous healing observed in juveniles [15, 145, 147, 228, 248-250]. We opted to 
trial our compound in a model comprising a full depth osteochondral defect in the 
femoral trochlea groove, where microfracture is used with a commercially available 
hyaluronic acid-based hydrogel (AuxiGel
TM
, Termira AB) [9], based on guidelines 
outlined by Reinholz et al. [251], the ICRS [252], and current standard-of-care 
practices in hospitals [229, 230]. 
As the basis of our experimental treatment relied on the interaction of HS16
+ve
 
with TGF-β1, it was necessary to determine that the rabbit TGF-β1 protein sequence 
was sufficiently conserved to human TGF-β1. Sequence alignment of rabbit and 
human TGF-β1 revealed that TGF-β1 was not only highly conserved across both 
species, but the identified heparin-binding domain was nearly identical (Fig. 4.8). 
More importantly, mean levels of TGF-β1 in the joint fluid of rabbits have been found 
to range from 112.7 pg/mL in young rabbits to 52.3 pg/mL in adult rabbits [88], while 
levels in anti-coagulated bone marrow aspirate were found to range from 190 – 881.8 
pg/mL in adult rabbits (n = 20) (Lim, Z. X. H., unpublished data). Separate studies 
have also reported increases in TGF-β1 of up to nanogram levels after platelet 
activation [146], and the presence of sufficient levels of TGF-β1 in the wound to 
stimulate cartilage repair [18]. As such, the use of exogenous TGF-β1 with our sugar 
treatments was precluded. 
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FIGURE 4.8. Sequence alignment of mature human and rabbit TGF-β1. Amino acid 
residues in the predicted heparin-binding domain of mature human TGF-β1 are 
coloured red and lysines (K) identified by the ‘Protect and Label’ technique are in 
bold.  
 
 A 12-week study was performed comparing the following groups: (1) control 
group treated with 60 μL of hydrogel (Gel alone) per defect; (2) defects treated with 
60 μL of hydrogel and 10 μg of HSPM (HSPM); (3) defects treated with 60 μL hydrogel 
and 10 μg of HS16+ve (HS16+ve), and (4) defects treated with 60 μL hydrogel and 10 
μg of HS16-ve (HS16-ve). Based on the earlier work presented in Chapter 2, 10 μg/mL 
of GAG was determined to be optimal for enhancing the effects of 1 ng/mL of TGF-
β1. As such, it was decided that a dose of 10 μg of GAG would be sufficient to 
achieve this optimal concentration within the defect, even after accounting for 
possible diffusion within the synovial cavity. Defects were created as described in the 
Methods section (Fig. 4.9). Two rabbits died of gastric stasis before the end of the 
trial and were therefore excluded from the analysis. 
At the end of the trial, whole femurs were harvested from the rabbits, fixed in 
10% (v/v) NBF and imaged macroscopically before being decalcified and processed 
for histology. Macroscopic observation of defects after 12 weeks revealed a slight 
difference between the control (Gel alone) and treatment groups with regard to tissue 
filling (Fig. 4.10). While there was an equal amount of variation in tissue filling 
within each treatment group, more defects in the control group were incompletely 
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filled relative to those in the other groups. While there were no significant differences 
in the ICRS I scores (Table A2) between the four treatment groups, the median scores 






were higher than those of Gel 
alone (Fig. 4.11). 
 
FIGURE 4.9. Osteochondral defect creation and gel implantation in rabbit model for 
cartilage injury. Femoral trochleas were exposed and 4 mm diameter defects created. 
Microfracture was then carried out before the implantation of the gel/HS treatments. 
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FIGURE 4.10. Macroscopic appearance of osteochondral defects after 12 weeks. 
Representative images of high-scoring (Well healed) (left column) and low-scoring 
(Poorly healed) (right column) repair tissue found in the various treatment groups at 
12 weeks post-surgery. Ruler markings in each image indicate 1 mm divisions. 
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FIGURE 4.11. Macroscopic scores of treatment groups. Scatter plot of ICRS I scores 
for each treatment group. (A) Middle line represents the mean score, error bars 
represent SE. (B) Line represents the median score. 
 
 A normal trochlea and one with an empty defect were used as benchmarks to 
gauge the degree of repair in our treatment samples (Fig. 4.12). Histological analysis 
revealed marked differences between the treatment groups in terms of appearance, 
integration and composition of repair tissue (Fig. 4.13). HS
PM
-treated samples most 
closely resembled the morphology of uninjured joints, with nearly complete 
remodelling of the sub-chondral bone and filling of the chondral space. The tissue in 
the chondral space was smooth and matched the curvature of the joint surface, but the 
defect margins were still clearly visible. HS16
-ve
-treated samples presented with 
nearly complete filling of the sub-chondral bone, although bone remodelling was 
more pronounced than that seen in HS
PM
 samples. The repair tissue in the chondral 
space was more uneven and fibrillated. HS16
+ve
-treated samples showed a mixture of 
bone and cartilage filling the sub-chondral space, with clearly visible defect margins. 
Defects in this group contained higher overall amounts of cartilage-like repair tissue 




 samples. Control samples 
exhibited the poorest healing response out of all the conditions tested. Defects in this 
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group were filled with the highest amount of cartilage-like tissue in the sub-chondral 
space. However, scores from the O’Driscoll (Fig. 4.14A, Table A3) and ICRS II (Fig. 
4.14C, Table A4) scoring systems showed no significant differences between the 
treatment groups. Interestingly, both the O’Driscoll (Fig. 4.14B) and ICRS II (Fig. 
4.14D) median scores for HS
PM
-treated samples were higher than those of the other 
treatment groups. 
 
FIGURE 4.12. Histology of an intact trochlea and one with an empty defect. (A) 
Sections were stained with Masson’s Trichrome, to detect collagen (blue), cytoplasm 
(red) and nuclei (black), and Safranin-O and Alcian blue, to detect GAGs (red and 
blue, respectively). Immunohistochemistry was used to determine Collagen Type II 
and Collagen Type I distribution. (B) Section demarcating the chondral and sub-
chondral layers in the sample. Scale bar: 1 mm 
 
 Tissue filling of the defect was determined by first identifying the borders of 
the chondral and sub-chondral spaces (Fig. 4.12B), superimposing a grid over the 
imaged sections and then measuring the amount of space filled for each histological 
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space. In terms of tissue filling, nearly all the samples exhibited complete sub-
chondral filling and high levels of chondral filling (Fig. 4.15). While there were no 
statistical differences between the tissue filling scores for all the treatment groups, the 




-treated samples were higher than those 
of HS16
+ve
 and Gel alone (Fig. 4.15B). The median percentage of sub-chondral filling 
in all samples was similar, but median percentage of chondral filling was found to be 
greater in HS16
-ve
-treated samples than that of HS
PM
-treated samples. Surprisingly, 
samples from the HS16
+ve
 group had the lowest median amount of tissue filling 
(overall, sub-chondral and chondral) out of the three HS compounds tested, although 
it should be noted that all three compounds had median scores that were higher than 
control samples (Gel), which is the current clinical standard-of-care treatment. 
  
FIGURE 4.13. Effects of HS fractions on in vivo cartilage repair. Representative 
images of the histology seen in each of the treatment groups at 12 weeks post-surgery. 
Scale bar: 1 mm 
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FIGURE 4.14. Histological scores of treatment groups. Scatter plots showing the (A, 
B) O’Driscoll and (C, D) ICRS II scores for each treatment group. (A, C) Middle line 
represents the mean score, error bars represent SE. (B, D) Line represents median 
score. 
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FIGURE 4.15. Tissue-filling scores of treatment groups. Scatter plots showing the 
(A) overall, (C) sub-chondral and (E) chondral filling scores for each treatment group. 
Middle line represents the mean score, error bars represent SE. (B, D, F) Middle line 
represents median scores. 
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 While informative, the tissue filling scores could not provide a clear picture of 
the type of tissue filling each defect, so it was necessary to examine the composition 
of the repair tissue in each defect. The composition of tissue filling the defects in each 
group appeared to correlate with histological scores and the median filling scores. 
Composition percentages were determined by expressing the amount of each type of 
tissue seen as a percentage of the total tissue in the respective tissue compartment 
(sub-chondral or chondral). HS
PM
-treated samples were predominantly filled with 
bony tissue in the sub-chondral space and a combination of hybrid and hyaline 
cartilage in the chondral space (Fig. 4.16). Hybrid cartilage is a combination of fibro- 
and hyaline cartilage that has an overlapping expression of both type I and type II 
collagen. Tissue composition profiles for HS16
-ve
 were similar to those of HS
PM
 
samples, while those of HS16
+ve
 were more similar to that of the control samples. It 
was interesting to note that the median tissue filling scores, rather than the mean 
scores, appeared to better correlate with the composition of repair tissue within the 





defects correlated with higher amounts of the desired tissue (i.e. bone in the sub-
chondral space and hyaline cartilage in the chondral layer) within the defects. 
Similarly, the lower median tissue filling scores seen in Gel and HS16
+ve
 samples also 
appeared to correlate with lower amounts of the desired tissue being formed within 
the defects. 
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FIGURE 4.16. Composition of repair tissue. Bar charts showing the average 
composition of (A) sub-chondral and (B) chondral repair tissue in each treatment 
group. (C) Tissue composition in the ideal healing response. 
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 Collectively the data show that treatment of full depth osteochondral defects 
with a single dose of sugar, in conjunction with microfracture and hydrogel 





 led to higher median scores than treatment with 
HS16
+ve
 across all the metrics used, though these differences were not significant. 
Whether this was a result of the nature of the defect model used or a matter of dose 
optimisation remains to be determined. 
 
4.4. Discussion 
 The in vitro and in vivo testing of any potential therapeutic is an essential part 
of its development process. Here we examined the effects of HS16
+ve
 in an in vitro 
system of chondrogenic differentiation and an in vivo model for cartilage repair. For 
the in vitro system, we utilised the TGF-β1-driven chondrogenic differentiation of 
hMSCs, as they are already regularly employed in clinical interventions [253]. We 
first report the baseline values for chondrogenic gene expression in hMSCs over the 
course of 21 days of differentiation, and examined the histology of the resulting 
chondrogenic pellets after 21 days. Expression of the chondrogenic genes SOX9, 
COMP and aggrecan was significantly higher in TGF-β1-treated pellets compared to 
control pellets, while collagen type 2α1 mRNA was only detected in the former. 
Unexpectedly, collagen 10α1 expression, a marker for chondrocyte hypertrophy that 
precedes osteochondral ossification [244], was significantly increased in TGF-β1-
treated pellets relative to control pellets. Differences in the deposition of GAGs within 
the control and TGF-β1-treated pellets were also observed. When TGF-β1 was pre-
complexed with heparin prior to its addition to the differentiation medium, dose-
dependent increases were noted in the expression of the early chondrogenic markers 
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SOX9 and COMP after 3 days of culture. However, there were no obvious changes in 
GAG deposition between pellets treated with 1 ng/mL TGF-β1 alone or with 10 
μg/mL heparin, while pellets treated with 10 ng/mL TGF-β1 had marginally more 
GAG staining, as determined by Alcian Blue. Differentiation in the presence of our 
HS variants saw increased COMP and aggrecan expression in HS16
+ve
-treated 




, but these levels were not always greater than 
those of heparin or 10 ng/mL TGF-β1. Histological analysis of the pellets at day 21 
also failed to highlight any marked difference in GAG deposition between the 
treatment groups, making it difficult to draw any conclusions. 
 A modified micromass culture system was chosen over the conventional, 
pellet-based, system for chondrogenic differentiation because of the improved 
differentiation efficiency described by Zhang et al. [174]. Contrary to their claims, 
our pellets were seen to lose weight as differentiation progressed. This could be due to 
our use of commercially prepared chondrogenic medium, where the cells were treated 
with the same batch of medium over the course of their differentiation instead of 
freshly prepared medium. Heparin pre-complexed with TGF-β1 was found to have no 
effects on the expression of SOX9 and COMP, both early chondrogenic markers, 
which contradicts our earlier findings on the effect of heparin on TGF-1-driven 
SMAD signalling. Despite the changes observed in gene expression after 3 days, 
histological analysis of the pellets after 21 days failed to demonstrate significant 
differences between heparin-treated pellets and their corresponding controls. Again, it 
remains to be determined if this is a true result or an effect of using commercially 
available medium. 
                                                                 142 
CONFIDENTIAL 







) revealed that the use of HS16
+ve
 with TGF-β1 led to an increase 





Additionally, gene expression in HS16
+ve
-treated pellets, with the exception of 
aggrecan, was comparable to that seen in heparin-treated pellets. However, the 
expression of SOX9, COMP and aggrecan observed in pellets treated with high (10 
ng/mL) TGF-β1 was found to be similar to pellets treated with low (1 ng/mL) TGF-
β1. This would suggest a down regulation of these transcripts as differentiation 
proceeds and the pellets start to hypertrophy in the high TGF-β1 samples, as shown 
by collagen type X upregulation [254, 255]. The decreased collagen type II mRNA 
expression also favours this hypothesis. It therefore appears that treatment of pellets 
with low doses of TGF-β1, relative to high doses, results in a temporal shift to the left, 
or retardation, in their gene expression profile. As such, the use of mRNA expression 
data at a single time point may not be sufficient to draw conclusions about the 
chondrogenic differentiation status of hMSCs, relative to positive controls of pellets 
treated with 10 ng/mL of TGF-β1. The lack of collagen type II expression in our HS-
treated samples could be attributed to the retarded differentiation of hMSCs when 
treated with 1 ng/mL of TGF-β1. 
 Differentiation in the presence of our HS variants over 21 days failed to 
produce significant histological differences in pellet morphology and GAG 
deposition. This might suggest that the changes observed in gene expression were 
insufficient to drive protein expression and the resulting morphological alteration. 
However, it has been reported that bovine MSCs are able to spontaneously 
differentiate into chondroblasts in pellet culture, without addition of TGF-β1 [235]. 
Our results from time course measurements of chondrogenic gene expression in 
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pellets treated with and without TGF-β1 suggest that hMSCs might also be able to 
spontaneously differentiate. This, together with the serum-free nature of chondrogenic 
cultures, raises questions about the effectiveness of current protocols in recapitulating 
the in vivo events of chondrogenesis, as both MSCs and chondrocytes have been 
shown to migrate towards serum [256]. The extensive research being carried out to 
improve the current in vitro culture system is further testament to the system’s 
shortcomings [12, 14, 82, 257-261]. As such, it was necessary to proceed to an in vivo 
model to examine the effects of our HS variants on cartilage repair. 
A rabbit model for cartilage repair was used for our in vivo study because of 
its widespread use [18, 145, 147, 248-250, 262] and the sequence homology that 
rabbit TGF-β1 shared with its human equivalent. Being easier to handle and cheaper 
to maintain, the use of rabbits also allowed a larger sample size. An osteochondral 
defect was chosen because of the inherent difficulty in creating chondral defects in 
rabbits, which have significantly thinner articular cartilage compared to humans 
[251]. Our goal was to examine the effects of our HS variants on cartilage repair when 
incorporated with the current standard of care treatment, which is the use of 
microfracture in conjunction with a hydrogel  [229, 230]. While our results showed 
that all four treatment groups performed equally well, the median scores appear to 
indicate that HS
PM
 might be able to improve the consistency of the healing outcome 
across all the different metrics used – macroscopic appearance, histological staining, 
and tissue filling and composition. More importantly, we also show that the use of our 
HS variants did not lead to poorer healing outcomes, relative to the gel and 
microfracture combination. 
 The unexpected results might be attributable to the nature of the defect used in 
our study. In an osteochondral defect, there is a need to fill the sub-chondral space 
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before repair can occur in the chondral space. Given the unrefined nature of HS
PM
, it 
is entirely plausible that it would have been able to bind to, and potentiate the activity 
of the torrent of growth factors that would have flooded into the defect site. Foremost 
amongst these factors would have been BMP-2 and the other growth factors necessary 
for bone healing, such as vascular endothelial growth factor (VEGF) [263, 264]. 
While we have shown that HS16
+ve
 is able to potentiate BMP-2 activity better than 
HS
PM
 in a mouse myoblast cell line, the purification process is likely to have reduced 
its ability to interact with non-TGF-1 superfamily members relative to HSPM. This 
altered growth factor binding capability could then have impeded the bone healing 




 The ability of HS16
+ve
 to potentiate the more abundant latent form of TGF-1, 
LTGF, compared to the mature, active form, could also be a factor in the 
unanticipated results. LTGF has been shown get activated through a number of 
mechanisms that include a drop in pH, release of proteases and/or reactive oxygen 
species, and via interactions with integrins [51, 64, 265], all of which are present in a 
wound site. The further activation of LTGF by HS16
+ve
 might have precipitously 
imbalanced the regulation of TGF-1 in the wound site in favour of a pro-
inflammatory response, which tends to hinder wound healing [266, 267].  
 Apart from the factors discussed thus far, more fundamental variables, such as 
reproducibility in defect creation, the dose of HS used and the duration of the study 
could have also been responsible for the variation in our results. The need to balance 
the use of controls versus the doses of HS used, while maintaining statistical power 
and keeping sample sizes manageable, saw us opting in favour of the former - testing 
                                                                 145 
CONFIDENTIAL 






 - for our pilot study. 
Adoption of a non-invasive method for assessing the degree of healing, like magnetic 
resonance imaging, would aid in overcoming the challenge of selecting an appropriate 
end point for future studies. Collectively, the data warrants the further examination of 
the ability of HS16
+ve
 to activate and potentiate LTGF in vivo, and the refinement of 
the surgical model used. 
 
4.5. Limitations of this study 
The in vitro chondrogenic differentiation of hMSCs is severely limited by both 
their sensitivity to the passage number [268], and the use of serum-free medium. 
Given the scarcity of MSCs in isolated/purchased cell preparations, there is often a 
need to balance the need for sufficient cell expansion with the need to minimise their 
time in culture to prevent phenotypic changes. When coupled with the inherent 
variability between donors, such a system can lead to highly variable results. In 
addition, the exclusion of serum from chondrogenic differentiation medium, while 
helpful in reducing experimental variability, further reduces any semblance the 
system may have to in vivo events, which raises questions about the precise relevance 
of data obtained. Attempts to quantify the amount of Alcian blue staining with 
imaging software, while possible, will be highly dependent on the spatial location of 
the sections being analysed, relative to the intact pellet. 
 Separately, logistical constraints necessitated the use of a single time point and 
single dose of HS in our animal study. Resources permitting, the inclusion of an 
earlier and later time point, along with a range of doses of the HS variants, would 
have enabled a more comprehensive evaluation of the effects of our sugars on in vivo 
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cartilage repair. Most importantly, it may be necessary to examine the effects of the 




 This chapter reports the use of HS16
+ve
 in an in vitro system of chondrogenic 
differentiation and an in vivo model or cartilage repair. The data indicate that while 
HS16
+ve
 was able to enhance the TGF-1-induced expression of a number of 




, the shortcomings of the applied 
in vitro system hampers our interpretation of the results. Our in vivo study 
unexpectedly showed that HS
PM
 administration, rather than HS16
+ve
, produced the 
most consistent healing outcome in an osteochondral defect. Whether this is due to the 
nature of the defect used or the unintended effect(s) of possible over activation of 
LTGF is still moot. Collectively, the data highlight both the need for a more refined 
system for the study of cartilage differentiation and healing in vitro and in vivo, and 
the further study of the consequences of HS16
+ve
-mediated activation of LTGF 
signalling. 
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CHAPTER 5.  CONCLUSIONS AND RECOMMENDATIONS 
5.1. Conclusions 
 This thesis set out to identify the structural determinants of the heparin-TGF-
β1 interaction with a longer view towards the development of a therapeutically 
relevant TGF-β1-binding HS variant. It was envisaged that the resulting HS variant 
could be used to potentiate the effects of endogenous TGF-β1, thus reducing or even 
eliminating the need for exogenous growth factor administration, particularly for 
cartilage repair. Based on the results presented here, the following conclusions can be 
drawn: 
1) There are indeed defined structural determinants for the interaction of TGF-β1 
with heparin. The minimum heparin chain length and sulphate distribution for 
the optimum binding of heparin to TGF-β1 have now been determined. 
Together with the direct identification of both predicted and novel heparin-
binding residues on the TGF-β1 homodimer, the data not only validates, but 
builds upon the original model proposed by Lyon et al. [68]. 
2) The relationship between heparin-TGF-β1 binding and bioactivity is not 
straightforward. An increase in binding does not necessarily lead to an 
enhancement in bioactivity, which provides compelling evidence for a 
relatively specific ‘sugar-code’ within the GAG for this particular HS-protein 
interaction [198, 225]. 
3) Information derived from the study of heparin-protein interactions is highly 
relevant to HS-protein interactions. The data show that the binding 
determinants for heparin-TGF-β1 interaction and bioactivity appeared to be 
enriched for in the affinity-isolated HS variant, HS16
+ve
, that was 
subsequently produced. 
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4) HS16+ve is compositionally and functionally distinct from HSPM and HS16-ve. 
It is able to bind to and potentiate TGF-β1-driven pSMAD signalling, and 
appears to have similar effects on LTGF-β1, in hMSCs. 
5) The use of either HSPM or its variants in the treatment of an osteochondral 
defect model in rabbits was at least as good as the current standard of care 
treatment. 
The data presented here allows one to posit that such heparin:HS comparisons 
can serve as an efficient template for the development of HS variants for other 
clinically relevant growth factors. The simplicity of the affinity isolation system, ease 
of handling of the isolated HS variants, and the resulting ability to reduce or remove 
levels of exogenous protein should lead to significant cost savings relative to current 
growth factor-based therapies. Additionally, the ability to avoid or reduce exogenous 
growth factor administration should significantly reduce the risks of untoward side 
effects [10]. 
 
5.2. On-going work and recommendations for future research 
5.2.1. Computational modelling of TGF-β1-heparin interactions and site-directed 
mutagenesis 
 To further extend our understanding of the heparin-TGF-β1 interaction, we 
have embarked on the computational modelling of the interaction of TGF-β1 with 
heparin oligosaccharides (dp2 to dp8). Such studies will improve the mapping of 
heparin-binding residues on TGF-β1 and will help to pave the way for the 
development of synthetic sugars. Preliminary studies indicate that when a dp4 is 
bound to TGF-β1, the 2-O-sulphate group is oriented away from the protein and 
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protrudes into the solvent (Yang and Wong, unpublished data). This group could then 
conceivably interfere with the binding of TGF-β1 to its receptors [269], which 
corresponds with our finding of how the lack of 2-O-sulphation enhances the 
potentiating effect that heparin has on TGF-β1.  
 Site-directed mutagenesis of the identified heparin-binding residues would 
also serve to validate the results obtained from our ‘Protect and Label’ experiment. 
The selective mutation of the identified heparin-binding lysines and other putative 
heparin-binding residues would aid in refining the model for heparin binding to TGF-
β1. 
5.2.2. Refinement of HS16 isolation and production 
 In order to further refine our HS production, one could envisage the 
incorporation of a size fractionation step after the isolation of HS16
+ve
. Such a step 
would allow the removal of HS chains smaller than a dp20 and possibly enhance the 
selectivity of the HS preparation. With the development of HS sequencing tools [126], 
improved knowledge of heparin-TGF-β1 interactions, and improved techniques for 
HS synthesis [270], one could foresee the eventual development of a synthetic version 
of HS16
+ve
, which will hopefully further reduce its off target effects while improving 
its specificity for TGF-β1. 
5.2.3. Role of HS/hep in LTGF-β1 regulation 
 Given the unexpected ability of HS16
+ve
 to potentiate the activity of LTGF-β1 
and the protein’s abundance in vivo, it would be interesting to further investigate the 
role of heparin/HS in LTGF-β1 regulation and determine if HS16+ve is able activate 
LTGF-β1. Basic gel shift experiments or SPR assays would allow us to determine if 
HS16
+ve
 actually activates LTGF-β1 or binds to TGF-β1 and prevents its binding to 
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LAP [63]. As heparin has been reported to be involved in the assembly and deposition 
of the large latent TGF-β1 complex within the ECM [64, 65], an investigation of the 
effects of HS16
+ve
 on these processes would be highly informative. With the reporting 
of the structure of porcine LTGF-β1 [51], the ‘Protect and Label’ approach for the 
identification of heparin-binding residues could also be employed to provide insight 
on the physical interaction between the two molecules.   
5.2.4. Refinement of in vitro and in vivo chondrogenic models 
 Having already discussed the shortcomings of the current in vitro 
chondrogenic differentiation model for hMSCs, it may be necessary to revert to using 
non-commercial differentiation medium (i.e. medium that we prepare ourselves). This 
would ensure that fresh aliquots of medium supplements are used at each medium 
change, instead of the current situation where the supplements are added to the 
medium and kept at 4°C for up to 21 days. Quantification of soluble GAG production 
in conjunction with the wet weights of the pellets would also aid in the objective 
assessment of their differentiation state. 
The in vivo data obtained from this pilot study, while proving highly 
informative, suggests that the design of our study needs refinement. Given the amount 
of healing seen in our control group, it may be necessary to employ an earlier time 
point (4-6 weeks) to give a clearer indication of the kinetics of the healing response. 
As our in vitro studies have suggested that HS16
+ve
 enhances TGF-β1 bioactivity only 
when pre-loaded with the growth factor, it may be necessary to pre-load our HS-gel 
constructs prior to implantation. While this would fall short of our original aim of 
doing away with exogenous growth factors, we expect to be able to load less TGF-β1 
(targeted final dose of ~1-5 ng/mL) compared to other groups, who have gone as high 
as 600 ng/mL of construct [145]. Alternatively, it may be necessary to adopt a two-
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stage implantation protocol, where a priming dose of HS16
+ve
 is added to the defect 
after microfracture to pre-bind activated TGF-β1, followed by implantation of the gel-
HS combination. A third approach would be to examine the effects of just HS16
+ve
 
over a range of doses, in order to determine the optimal dose of HS to employ prior to 
embarking on a broader study with the remaining sugar variants. This approach would 
enable the inclusion of additional time points without the need to sacrifice statistical 
power. The inclusion of MRI monitoring of defect healing would also provide a non-
invasive method for the real time monitoring of defect healing. 
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APPENDIX A: SUPPLEMENTARY FIGURES AND TABLES 
 
FIGURE A1. Optimisation of heparin dosing for GAG ELISA. Error bars represent 
standard deviation, n = 3. 
 
 
FIGURE A2. Optimisation of protein elution conditions for the “Protect and Label” 
technique. (A) A range of elution buffers was used to elute the acetylated TGF-β1 
from the heparin microcolumn. Samples were collected, resolved by SDS-PAGE and 
silver stained. (B) Silver stained gel of quality control samples of TGF-β1 taken at the 
indicated stages of the “Protect and Label” experiment. TGF-β1 was successfully 
eluted with 2% (v/v) SDS, but the use of the detergent rendered the final sample 
unsuitable for subsequent MS analysis. RapiGest was subsequently employed instead. 
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FIGURE A3. Chymotrypsin cleavage sites in TGF-β1 as determined by the “Protect 
and Label” technique. 
 
 
FIGURE A4. Effect of heparin sulphation on TGF-β1 signalling in hMSCs. Cells 
from a separate donor (Donor B) were treated with TGF-β1 (1 ng/ml), pre-incubated 
with 10 μg/ml of the various selectively desulphated (2-O-de, 6-O-de or N-de) or fully 
sulphated heparin (Hep) for 10 min at room temperature, and lysed after 6 h. 
Phosphorylated SMAD2 (pSMAD2) and SMAD3 (pSMAD3), total SMAD2/3 and 
actin levels were determined by Western blotting. Densitometry of (A) pSMAD2 and 
(B) pSMAD3 levels. Error bars represent standard error, n = 2. 
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FIGURE A5. Predicted conformations of the TGF-β1 peptide used for HS16+ve 
isolation. (A) Native peptide conformation in the full length protein. (B-F) Predicted 
peptide conformations in solution, based on PEP-FOLD modelling [216-218]. Arg 
and Lys residues are coloured blue. 
 
                                                                 180 
CONFIDENTIAL 






Protein Length Organisms 
 
Gene Name Protein Name 
 
 
P01137 44997 390 Homo Sapiens TGFB1 Transforming growth factor beta-1 
 
 
    
Sequence of Human TGF-β1, labelled peptides covered in red. 
1 MPPSGLRLLL LLLPLLWLLV LTPGRPAAGL STCKTIDMEL VKRKRIEAIR 
51 GQILSKLRLA SPPSQGEVPP GPLPEAVLAL YNSTRDRVAG ESAEPEPEPE 
101 ADYYAKEVTR VLMVETHNEI YDKFKQSTHS IYMFFNTSEL REAVPEPVLL 
151 SRAELRLLRL KLKVEQHVEL YQKYSNNSWR YLSNRLLAPS DSPEWLSFDV 
201 TGVVRQWLSR GGEIEGFRLS AHCSCDSRDN TLQVDINGFT TGRRGDLATI 
251 HGMNRPFLLL MATPLERAQH LQSSRHRRAL DTNYCFSSTE KNCCVRQLYI 
301 DFRKDLGWKW IHEPKGYHAN FCLGPCPYIW SLDTQYSKVL ALYNQHNPGA 
351 SAAPCCVPQA LEPLPIVYYV GRKPKVEQLS NMIVRSCKCS 
 
Peptides and their modifications with mascot score ≥20 identified by mass spectrometry 
Observed Mr(expt) Mr(calc) Delta Score Expect Peptide 
500.8379 999.6612 999.4960 0.1652 26 0.88 RK(Bi)DLGW 
534.3387 1066.6628 1068.5062 -1.8434 38 0.032 IHEPK(Bi)GY  
566.8395 1131.6644 1131.5746 0.0897 29 0.71 IDFRK(Bi)DL 
596.4235 1190.8325 1190.6084 0.2241 31 1.7 IDFRK(Ac)DLGW  
678.9255 1355.8364 1355.6808 0.1556 20 0.69 RK(Bi)DLGWK(Ac)W  
679.3422 1356.6698 1355.6808 0.9889 24 0.33 RK(Ac)DLGWK(Bi)W  
687.4257 1372.8368 1374.6754 -1.8386 33 0.23 IDFRK(Bi)DLGW  
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Observed Mr(expt) Mr(calc) Delta Score Expect Peptide 
690.4258 1378.8370 1378.6802 0.1567 33 0.091 SLDTQYSK(Bi)VL  
700.4260 1398.8374 1398.6054 0.2321 40 0.015 SNM(Ox)IVRSC(Ca)K(Ac)C(Ca)S  
701.0093 1400.0041 1399.7823 0.2218 27 0.16 YVGRK(Ac)PK(Ac)VEQL 
711.5929 1421.1713 1420.7860 0.3853 32 0.68 VGRK(Ac)PK(Bi)VEQL 
713.5096 1425.0047 1424.6911 0.3137 31 0.1 K(Ac)WIHEPK(Bi)GY  
770.0110 1538.0074 1537.7136 0.2938 32 0.016 IHEPK(Bi)GYHANF  
783.4280 1564.8414 1566.6775 -1.8361 66 0.00078 SNMIVRSC(Ca)K(Bi)C(Ca)S 
523.2551 1566.7435 1566.6775 0.0660 25 0.28 SNMIVRSC(Ca)K(Bi)C(Ca)S 
792.3449 1582.6752 1583.8494 -1.1742 43 0.012 YVGRK(Bi)PK(Ac)VEQL  
793.0115 1584.0085 1582.6724 1.3361 51 0.0029 SNM(Ox)IVRSC(Ca)K(Bi)C(Ca)S  
793.0949 1584.1752 1583.8494 0.3259 42 0.27 YVGRK(Ac)PK(Bi)VEQL  
529.3386 1584.9939 1583.8494 1.1445 23 0.75 YVGRK(Ac)PK(Bi)VEQL  
803.5118 1605.0090 1604.8531 0.1560 20 2.9 VGRK(Bi)PK(Bi)VEQL  
805.5118 1609.0091 1608.7581 0.2510 22 0.12 K(Bi)WIHEPK(Bi)GY  
843.4294 1684.8443 1685.7501 -0.9058 23 0.2 SSTEK(Ac)NC(Ca)C(Ca)VRQLY  
569.5895 1705.7468 1706.7538 -1.0070 34 0.094 SSTEK(Bi)NC(Ca)C(Ca)VRQL  
854.4297 1706.8448 1706.7538 0.0910 37 0.021 SSTEK(Bi)NC(Ca)C(Ca)VRQL 
936.0150 1870.0154 1869.8172 0.1982 36 0.018 SSTEK(Bi)NC(Ca)C(Ca)VRQLY  
624.7575 1871.2507 1869.8172 1.4336 25 0.23 SSTEK(Bi)NC(Ca)C(Ca)VRQLY  
1007.9333 2013.8521 2013.8529 -0.0008 40 0.0015 C(Ca)FSSTEK(Bi)NC(Ca)C(Ca)VRQL  
1090.0186 2178.0227 2176.9162 1.1065 53 0.00017 C(Ca)FSSTEK(Bi)NC(Ca)C(Ca)VRQLY  
977.0159 2928.0260 2927.4424 0.5836 39 0.007 VGRK(Bi)PK(Bi)VEQLSNMIVRSC(Ca)KC(Ca)S  
984.1828 2949.5265 2948.4492 1.0773 26 0.044 YVGRK(Ac)PK(Bi)VEQLSNMIVRSC(Ca)K(Ac)C(Ca)S  
984.2661 2949.7765 2948.4492 1.3273 26 0.094 YVGRK(Bi)PK(Ac)VEQLSNMIVRSC(Ca)K(Ac)C(Ca)S  
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Bi = Biotinylated 
Ac = Acetylated 
Ca = Carbomidomethylated 
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TABLE A2. ICRS I macroscopic cartilage repair assessment scoring criteria 
Criteria Points  
 
Degree of Defect Repairs 
 
* In level with surrounding cartilage 
* 75% repair of defect depth 
* 50% repair of defect depth 
* 25% repair of defect depth 








Integration to Border 
Zone 
 
* Complete integration with surrounding 
cartilage 
* Demarcating border < 1mm 
* 3/4 of graft integrated, 1/4 with a notable 
border 
>1mm width 
* 1/2 of graft integrated with surrounding 
cartilage, 
1/2 with a notable border > 1mm 













* Intact smooth surface 
* Fibrillated surface 
* Small, scattered fissures or cracs 
* Several, small or few but large fissures 











Grade I    normal 
Grade II   nearly normal 
Grade III  abnormal 








TABLE A3. O’Driscoll histological scoring criteria for cartilage repair 
Nature of the predominant tissue Score 
 
Cellular morphology 
 Hyaline articular cartilage 4 
Incompletely differentiated mesenchyme 2 
Fibrous tissue 0 
 
Safranin-O staining of the matrix 
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Structural characteristics   
 
Surface regularity 
 Smooth and intact 3 
Superficial horizontal lamination 2 
Fissures: 25–100% of the thickness 1 
Severe disruption, including fibrillation 0 
 
Structural integrity 
 Normal 2 
Slight disruption, including cysts 1 
Severe disintegration 0 
 
Thickness 
 100% of normal adjacent cartilage 2 
50–100% of normal cartilage 1 
<50% of normal cartilage 0 
 
Bonding to the adjacent cartilage 
 Bonded at both ends of graft 2 





Absence of cellular changes resulting from degeneration   
 
Hypocellularity 
 Normal cellularity 3 
Slight hypocellularity 2 
Moderate hypocellularity 1 
Severe hypocellularity 0 
 
Chondrocyte clustering 
 No clusters 2 
<25% of the cells 1 
5–100% of the cells 0 
 
Absence of degenerative changes in adjacent cartilage 
 Normal cellularity, no clusters, normal staining 3 
Normal cellularity, mild clusters, moderate staining 2 
Mild or moderate hypocellularity, slight staining 1 
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TABLE A4. ICRS II histological scoring parameters 
Histological Parameter Score 
1. Tissue morphology (viewed under 
polarized light) 
0%: Full-thickness collagen fibers 
100%: Normal cartilage birefringence 
2. Matrix staining (metachromasia) 
0%: No staining 
100%: Full metachromasia 
3. Cell morphology 
0%: No round/oval cells 
100%: Mostly round/oval cells 




5. Surface architecture 
0%: Delamination, or major 
irregularity 
100%: Smooth surface 
6. Basal integration 
0%: No integration 
100%: Complete integration 
7. Formation of a tidemark 
0%: No calcification front 
100%: Tidemark 
8. Subchondral bone abnormalities/marrow 
fibrosis 
0%: Abnormal 




10. Abnormal calcification/ossification 
0%: Present 
100%: Absent 




12. Surface/superficial assessment 
0%: Total loss or complete disruption 
100%: Resembles intact articular 
cartilage 
13. Mid/deep zone assessment 
0%: Fibrous tissue 
100%: Normal hyaline cartilage 
14. Overall assessment 
0%: Bad (fibrous tissue) 
100%: Good (hyaline cartilage) 
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APPENDIX B: SUPPLEMENTARY INFORMATION FOR MATERIALS AND 
METHODS 
Antibodies 
Anti-Actin, Clone C4 monoclonal antibody (Cat. No. MAB1501R, Merck Millipore, 
MA, USA) 
Anti-Heparan Sulfate, purified monoclonal antibody (clone F58-10E4) (Cat. No. 
370255-1, AMS Biotechnology, Abingdon, UK) 
Anti-mouse IgM-FITC (Cat. No. 553408, BD Pharmingen
TM
, Becton, Dickinson and 
Company, NJ, USA) 
Anti-TGF-β1 mAb (Clone 141322) (Cat. No. MAB2401, R&D Systems Inc, MN, 
USA) 
Collagen I Antibody (COL-1) (Cat. No. NB600-450, Novus Biologicals, CO, USA) 
Collagen II Antibody (Cat. No. NB100-91715, Novus Biologicals, CO, USA) 
Collagen type II alpha 1 chain (COL2A1) mAb (Cat. No. AF5710, Acris Antibodies, 
Inc., CA, USA)  
Goat polyclonal Secondary Antibody to Mouse IgG – H&L (Biotin) (Cat. No. 
ab6788, Abcam, Cambridge, UK)) 
Phospho-Smad2 (Ser465/467) (138D4) Rabbit mAb (Cat. No. 3108, Cell Signaling 
Technology, MA, USA) 
Phospho-Smad3 (Ser423/425) (C25A9) Rabbit mAb (Cat. No. 9520, Cell Signaling 
Technology, MA, USA) 
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Smad2/3 Antibody (Cat. No. 3102, Cell Signaling Technology, MA, USA) 
Cell culture 
Dulbecco’s Modified Eagles Medium, Low glucose (DMEM-LG) (Cat. No. 
SH30021.01, HyClone
TM
, Thermo Fisher Scientific, MA, USA) 
Fetal Calf Serum (FCS) (Cat. No. SH30396.03, HyClone
TM
, Thermo Fisher Scientific, 
MA, USA) 
L-glutamine 200mM (100x) (Cat. No. 25030-081, Gibco, Life Technologies, CA, 
USA) 
Penicillin-Streptomycin (10,000 U/mL) (Cat. No. 15140-122, Gibco, Life 












 column (HALO, C18, 90 Å, 2.7 µm, 75 μm (ID) x 100 mm length) (New 
Objectives, MA, USA) 
ProPac PA1 column (4 mm x 250 mm) (Cat. No. 039658, Thermo Fisher Scientific, 
MA, USA) 
TSKgel G3000PWxl column (7.8 mm x 30 cm) (Cat. No. 08021, TOSOH Corp., 
Tokyo, Japan) 
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TSKgel G4000PWxl column (7.8 mm x 30 cm) (Cat. No. 08022, TOSOH Corp., 
Tokyo, Japan) 
Enzymes 
α-Chymotrypsin from bovine pancreas (Cat. No. C 6423, Sigma-Aldrich, MO, USA) 




 –Alkaline Phosphatase (Cat. No. E2636, Sigma-Aldrich, MO, USA) 
Heparinase I (Cat. No. HEP-ENZ I, Iduron Ltd, Manchester, UK) 
Heparinase I (Cat. No. 50-010, Ibex Technologies Inc., Quebec, Canada) 
Heparinase II (Cat. No. HEP-ENZ II, Iduron Ltd, Manchester, UK) 
Heparinase II (Cat. No. 50-011, Ibex Technologies Inc., Quebec, Canada) 
Heparinase III (Cat. No. HEP-ENZ III, Iduron Ltd, Manchester, UK)  
Heparinase III (Cat. No. 50-012, Ibex Technologies Inc., Quebec, Canada) 
Plasmin from human plasma (Cat. No. P1867, Sigma-Aldrich, MO, USA) 
Proteinase K (Cat. No. P2308, Sigma-Aldrich, MO, USA) 
Trypsin (1:250) powder (Cat. No. 27250-018, Gibco, Life Technologies, CA, USA) 
Heparin derivatives and HS 
Heparan sulphate sodium salt from porcine intestinal mucosa (HS
PM
) (Cat. No. HO-
10697, Celsus Laboratories Inc, Ohio, USA) 
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Heparin sodium salt from porcine intestinal mucosa (Cat. No. H3149-100KU, Sigma-
Aldrich, MO, USA) 
Heparin Oligosaccharides (dp4, dp6, dp8, dp10, dp12, dp14, dp16, dp18, dp20, dp22, 
dp24) (Cat. No. HO04, HO06, HO08, HO10, HO12, HO14, HO16, HO18, HO20, 
HO22, HO24, Iduron Ltd, Manchester, UK) 
Selectively desulphated heparin standards (2-O, 6-O and N-desulphated heparin) (Cat. 
No. DSH001/2, DSH002/6, DSH003/N, Iduron Ltd, Manchester, UK) 
Immunohistochemistry (IHC) reagents 
Bond
TM




 Dewax (Cat. No. AR9222, Leica Biosystems, Nussloch GmbH, Germany) 
Bond
TM
 Primary Antibody Diluent (Cat. No. AR9352, Leica Biosystems, Nussloch 
GmbH, Germany) 
Kits 
BCA Protein Assay Reagent (Cat. No. 23225, Thermo Fisher Scientific, MA, USA) 
Bond
TM
 Polymer Refine Detection Kit (Cat. No. DS9800, Leica Biosystems, 
Nussloch GmbH, Germany) 
hMSC Differentiation BulletKit
®
 - Chondrogenic (Cat. No. PT-3003, Lonza, MD, 
USA) 
SuperScript® VILO™ cDNA Synthesis Kit (Cat. No. 11754, Life Technologies, CA, 
USA) 
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TaqMan® Fast Universal PCR Master Mix (2X), no AmpErase® UNG (Cat. No. 
435042, Life Technologies, CA, USA) 
Primary cells and cell lines  
Poietics
®
 Bone Marrow Mono-Nuclear Cells (Cat. No. 2M-125E, Lot No. 0F4607, 
Lonza, MD, USA) 





 Gene Expression Assays (Cat. No. 4331182, Life Technologies, CA, USA) 
 Aggrecan (ACAN) (Assay ID: Hs00153936_m1) 
 Cartilage oligomeric matrix protein (COMP) (Assay ID: Hs00164359_m1) 
 Collagen, type II, alpha 1 (COL2α1) (Assay ID: Hs00264051_m1) 
 Collagen, type X, alpha 1 (COL10α1) (Assay ID: Hs00166657_m1) 
 Hypoxanthine phosphoribosyltransferase 1 (HPRT1) (Assay ID: 
Hs01003267_m1)  
 SRY (sex determining region Y)-box 9 (SOX9) (Assay ID: Hs00165814_m1) 
Protect and Label reagents 
C18 ZipTip (Cat. No. ZTC18S096, Merck Millipore, MA, USA) 
RapiGest
TM
 SF Surfactant (Cat. No. 186001861, Waters Corporation, MA, USA) 
Radiochemicals 
3
H-heparin (0.35 mCi/mg) (Cat. No. NET476, Perkin Elmer, MA, USA) 
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Recombinant proteins 
Recombinant Human TGF-β1 (Cat. No. 100-21C, PeproTech, Rocky Hill, NJ, USA) 
Recombinant Human Latent TGF-β1 (Cat. No. 299-LT/CF, R&D Systems Inc, MN, 
USA) 
Other materials 
3M™ Vetbond™ Tissue Adhesive (Cat. No. 1469SB, 3M, MN, USA) 
AuxiGel™ Injectable Hydrogel Scaffold (Termira AB, Stockholm, Sweden) 
β-Glycerophosphate disodium salt hydrate (Cat. No. G6251, Sigma-Aldrich, MO, 
USA) 




 NHS-Biotin (Cat. No. 20217, Thermo Fisher Scientific, MA, USA) 
Hoechst 33342, Trihydrochloride, Trihydrate (Cat. No. H1399, Life Technologies, 
CA, USA) 
L-Ascorbic acid 2-phosphate sesquimagnesium salt hydrate (Cat. No. A8960, Sigma-
Aldrich, MO, USA) 
Minisart
®
 RC15 Syringe Filters (Cat. No. 17761, Sartorius Stedim, Goettingen, 
Germany) 
Protease Inhibitor Cocktail Set III, EDTA-Free (Cat. No. 539134, Calbiochem, Merck 
Millipore, MA, USA) 
Sample Buffer, Laemmli 2× Concentrate (Cat. No. S3401, Sigma-Aldrich, MO, USA) 
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SB 431542 hydrate (Cat. No. S4317, Sigma-Aldrich, MO, USA) 
SIGMAFAST
™
 p-Nitrophenyl phosphate Tablets (Cat. No. N2770, Sigma-Aldrich, 
MO, USA) 
TRIzol® Reagent (Cat. No. 15596018, Life Technologies, CA, USA) 
Vivaspin 2, Hydrosart (Cat. No.VS02H91, Sartorius Stedim, Goettingen, Germany) 
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APPENDIX C: PUBLICATIONS AND PATENTS 
Manuscript 1: In preparation 
Structural determinants of heparin-transforming growth factor-β1 interactions and 
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